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Abstract
The PAndemic INfluenza Triage in the Emergency
Department (PAINTED) pilot cohort study
Steve Goodacre,* Andy Irving, Richard Wilson, Daniel Beever
and Kirsty Challen
School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
*Corresponding author s.goodacre@sheffield.ac.uk
Background: Research needs to be undertaken rapidly in the event of an influenza pandemic to develop
and evaluate triage methods for people presenting to the emergency department with suspected
pandemic influenza.
Objectives: We aimed to pilot a research study to be undertaken in a pandemic to identify the most
accurate triage method for patients presenting to the emergency department with suspected pandemic
influenza. The objectives of the pilot study were to develop a standardised clinical assessment form and
secure online database; test both using data from patients with seasonal influenza; seek clinician views on
the usability of the form; and obtain all regulatory approvals required for the main study.
Design: Study methods were piloted using an observational cohort study and clinician views were sought
using qualitative, semistructured interviews.
Setting: Six acute hospital emergency departments.
Participants: Patients attending the emergency department with suspected seasonal influenza during
winter 2012–13 and clinicians working in the emergency departments.
Main outcome measures: Adverse events up to 30 days were identified, but analysis of the pilot data
was limited to descriptive reporting of patient flow, data completeness and patient characteristics.
Results: Some 165 patients were identified, of whom 10 withdrew their data, leaving 155 (94%) for
analysis. Follow-up data were available for 129 of 155 (83%), with 50 of 129 (39%) being admitted to
hospital. Three cases (2%) were recorded as having suffered an adverse outcome. There appeared to be
variation between the hospitals, allowing for small numbers. Three of the hospitals identified 150 of 165
(91%) of the patients, and all 10 withdrawing patients were at the same hospital. The proportion with
missing follow-up data varied from 8% to 31%, and the proportion admitted varied from 4% to 85%
across the three hospitals with meaningful numbers of cases. All of the deaths were at one hospital. There
was less variation between hospitals in rates of missing data, and for most key variables missing rates were
between 5% and 30%. Higher missing rates were recorded for blood pressure (39%), inspired oxygen
(43%), capillary refill (36%) and Glasgow Coma Scale score (43%). Chest radiography was performed in
51 of 118 cases, and electrocardiography in 40 of 111 cases with details recorded. Blood test results were
available for 32 of 155 cases. The qualitative interviews revealed generally positive views towards the
standardised assessment form. Concerns about lack of space for free text were raised but counterbalanced
by appreciation that it fitted on to one A4 page. A number of amendments were suggested but only three
of these were suggested by more than one participant, and no suggestions were made by more than
two participants.
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Conclusions: A standardised assessment form is acceptable to clinicians and could be used to collect
research data in an influenza pandemic, but analysis may be limited by missing data.
Future work: An observational cohort study to identify the most accurate triage method for predicting
severe illness in emergency department attendees with suspected pandemic influenza is set up and ready
to activate if, or when, a pandemic occurs.
Trial registration: Current Controlled Trials ISRCTN56149622.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 19, No. 3. See the NIHR Journals Library website
for further project information.
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Glossary
Area under the receiver operator characteristic curve (c-statistic) A measure of the discriminant
value of a risk prediction score.
Community Assessment Application System Tool A decision pathway for determining which patients
with suspected pandemic influenza require hospital assessment and admission; it forms the basis of the
swine flu hospital pathway.
CURB-65 A risk prediction score for pneumonia, based on confusion, urea level, respiratory rate, blood
pressure and age > 65 years.
Ethics and Confidentiality Committee A subcommittee of the National Information Governance Board.
Pandemic Modified Early Warning Score A risk score for pandemic influenza, based on physiological
variables, age, social factors, chronic disease and performance status.
SMART-COP A risk prediction score for pneumonia, based on systolic blood pressure, multiple lobes
involvement on chest X-ray, albumin level, respiration, tachycardia, confusion, oxygenation and pH.
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xiii
List of abbreviations
AVPU alert, verbally responsive,
responsive to pain or unconscious
BP blood pressure
CAF clinical assessment form
CAG Confidentiality Advisory Group
CI confidence interval
CTRU Clinical Trials Research Unit
CXR chest X-ray
ECC Ethics and Confidentiality
Committee
ECG electrocardiogram
GCS Glasgow Coma Scale
GP general practitioner
HPA Health Protection Agency
ICNARC Intensive Care National Audit and
Research Centre
NIGB National Information Governance
Board
ONS Office for National Statistics
PAC Privacy Advisory Committee
PAINTED PAndemic INfluenza Triage in
Emergency Department
PMEWS Pandemic Modified Early Warning
Score
REC Research Ethics Committee
ScHARR School of Health and Related
Research
SD standard deviation
SECF Sheffield Emergency Care Forum
SwiFT Swine Flu Triage
WCC white cell count
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Plain English summary
An influenza pandemic occurs when influenza spreads rapidly across a large population. If this happens,there will be a big increase in the number of patients attending hospital emergency departments.
Triage is the process of quickly and accurately identifying patients at high risk of serious illness who need
urgent hospital treatment. Triage methods need to be developed and tested in a pandemic to ensure that
they are accurate.
The PAINTED (PAndemic INfluenza Triage in the Emergency Department) study is planned to be activated
if a pandemic occurs. We tested the PAINTED study research methods by developing a standardised
clinical assessment form that could both collect research data and be used as regular clinical notes, and
then tested use of the form in patients with seasonal influenza across six hospitals. We also interviewed
12 doctors and nurses to find out what they thought of the form.
We used the standardised form to collect data from 155 patients with suspected influenza during winter
2012–13. We were able to collect and analyse data, but some data were missing and this could cause
problems in a pandemic study. Staff views on the form were generally positive, indicating that they found
it acceptable and usable.
Over 40 hospitals across the UK have now been signed up to take part in the PAINTED study, and
regulatory approvals have been secured to allow the study to start if, or when, an influenza
pandemic occurs.
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Scientific summary
Background
An influenza pandemic could place huge demands upon emergency departments and acute hospital
services. Triage methods are required to identify patients who are at high risk of adverse outcome for
hospital admission and critical care, and patients who are at low risk of adverse outcome, who can be
discharged home with self-care advice. In this situation, triage refers to the whole process of emergency
department assessment, including diagnostic tests, if appropriate, to determine referral and treatment
decisions rather than a brief initial assessment to determine priority for medical assessment.
Existing triage methods for suspected pandemic influenza have limited accuracy and have not been fully
evaluated in a pandemic. Research is therefore required to determine the diagnostic accuracy of existing
triage methods in a pandemic; refine existing methods; and explore whether or not new methods with
improved accuracy can be developed. To undertake research in a pandemic we need to prepare research
processes, secure regulatory processes in advance and identify potential barriers to successful completion.
Objectives
We aimed to prepare and pilot a study to be undertaken in an influenza pandemic to identify the most
accurate triage method for predicting severe illness among patients attending the emergency department
with suspected pandemic influenza. The objectives of the main pandemic study will be to:
1. determine the discriminant value of emergency department triage methods for predicting severe illness
in patients presenting with suspected pandemic influenza
2. determine the discriminant value of presenting clinical characteristics and routine tests for identifying
severe illness
3. determine the independent predictive value of presenting clinical characteristics and routine tests for
severe illness
4. develop two new triage methods based upon (1) presenting clinical characteristics alone and
(2) presenting clinical characteristics, electrocardiogram (ECG), chest X-ray (CXR) and routine blood
test results.
The objectives of the pilot phase were to:
1. develop and test the use of a standardised clinical assessment form (CAF) that could be used for both
clinical record documentation and research data collection during a pandemic
2. develop and test a secure online database to allow efficient data management in a pandemic
3. analyse pilot data from patients with seasonal influenza to ensure that data are reasonably complete
and within expected ranges
4. seek clinician views on the usability of the standardised CAF
5. obtain all regulatory approvals required for the main study so that it can be activated rapidly in the
event of a pandemic.
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Methods
The main pandemic study
This will be a prospective observational cohort study of patients attending the emergency department with
suspected pandemic influenza. Adults and children presenting to the emergency departments of the
participating hospitals with suspected influenza will be included if they meet the clinical diagnostic criteria
in operation at the time of the pandemic. The assessing clinician will determine eligibility and complete a
standardised CAF if the patient is considered to have suspected influenza. The standardised CAF will
record potential predictors of adverse outcome, including known predictors and variables used in existing
triage methods.
Patients will be followed up until 30 days after attendance by hospital record review to identify adverse
outcomes. Patients who die or require respiratory, cardiovascular or renal support will be defined as having
an adverse outcome. If they survive to 30 days without requiring respiratory, cardiovascular or renal
support they will be defined as having no adverse outcome. We will also record whether they are treated
with antiviral agents or antibiotics, and the length and location of any hospital stay.
Analysis will estimate the discriminant value of existing triage methods (CURB-65, the Pandemic Modified
Early Warning Score, the swine flu hospital pathway, the SMART-COP score and the SwiFT score), clinical
predictors and diagnostic tests for predicting adverse events up to 30 days. We will also use multivariate
analysis to develop two new triage methods based on presenting (1) clinical characteristics alone (age,
gender, pregnancy, obesity, comorbidities, physiological variables) and (2) characteristics, routine blood
tests and CXR), if data allow. The sample size will ultimately depend upon the size and severity of the
pandemic. We have planned for a sample size of 20,000 cases, including 200 (1%) with an adverse
outcome, recruited across 40 hospitals. A sample of 150 with an adverse outcome will allow us to estimate
a c-statistic of a triage method, clinical variable or test with a standard error of 0.03 (assuming the true
c-statistic was 0.8).
The pilot study
We developed a standardised CAF and online database to collect data from patients presenting to the
emergency department with suspected pandemic influenza. We then tested the form, database and other
study processes in a pilot study of patients presenting to six hospitals with suspected seasonal influenza in
winter 2012–13. Patient selection, data collection, follow-up and outcome definitions were as planned for
the pandemic study. Analysis was limited to descriptive reporting of patient flow, data completeness and
patient characteristics.
Face-to-face, semistructured interviews were undertaken with 12 clinicians, who were likely to be
undertaking patient assessment in a pandemic, to determine their views towards the standardised CAF
and identify any improvements that could make the form more usable. Data from the interviews were
analysed using the framework approach.
Results
The standardised CAF and secure online database were successfully developed and used to collect data in
winter 2012–13. Some 165 patients with suspected influenza were identified across the six participating
hospitals and had CAFs completed. Ten patients subsequently withdrew their data from the study leaving
155 (94%) available for analysis. Follow-up data were available from 129 of 155 patients at 30 days
(83%). Of these, 50 of 129 (39%) were admitted to hospital, with a mean length of stay of 3.9 days
(median 2 days, range 0–22 days). Three cases (2%) were recorded as having suffered an adverse
outcome. All three died; two also received respiratory, cardiovascular and/or renal support.
SCIENTIFIC SUMMARY
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There appeared to be variation between the hospitals, allowing for small numbers. Three of the hospitals
identified 150 of 165 (91%) of the patients and all 10 withdrawing patients were at the same hospital.
The proportion with missing follow-up data varied from 8% to 31% and the proportion admitted varied
from 4% to 85% across the three hospitals with meaningful numbers of cases. All of the deaths were
at one hospital. There was less variation between hospitals in rates of missing data, and for most key
variables, missing rates were between 5% and 30%. Higher missing rates were recorded for blood
pressure (BP) (39%), inspired oxygen (43%), capillary refill (36%) and Glasgow Coma Scale score (43%).
The mean age of the cohort was 31 years (median 26.5 years, range 1–92 years) with 49 of 127 (39%)
aged 0–16 years. There were 72 males and 71 females. Influenza was thought by the clinician to be the
most likely diagnosis in 34 of 155 cases (22%). Mean symptom duration was 5.6 days (median 3 days,
range 1–56 days). Performance status among those with usable data for this variable was unrestricted/
normal in 78 (67%), limited by strenuous activity in 7 (6%), limited by non-strenuous activity in 25 (21%),
limited by self-care in five (4%) and bed-/chair-bound in two (2%). Social isolation (defined as living alone
or having no fixed abode) was reported by 27 patients (16%). Chronic diseases were recorded with the
following frequencies: heart disease,18; renal impairment, six; steroid therapy, one; asthma, 17; other
chronic lung disease, 14; diabetes, nine; active malignancy, one; and immunosuppression, one.
Mean [standard deviation (SD)] physiological measures were temperature 37.8 °C (SD 1.0°C), pulse rate
108 beats/minute (SD 28 beats/minute), respiratory rate 25 breaths/minute (SD 10 breaths/minute), systolic
BP 124mmHg (SD 23mmHg), diastolic BP 71mmHg (SD 13mmHg) and oxygen saturation 96% (SD 3%).
CXR was normal in 28, abnormal in 23 and not done in 67 of the 118 cases with details recorded. ECG
was normal in 26, abnormal in 14 and not done in 71 of the 111 cases with electrocardiography details
recorded. Blood test results were available for 32 of 155 cases.
The qualitative interviews revealed generally positive views towards the standardised CAF. Most clinicians
felt that the content was appropriate and usable. The structure was felt to be clear, simple, concise and
logical, with some participants commenting that it mirrored their own practice of taking notes. Concerns
about lack of space for free text were raised but counterbalanced by appreciation that it fitted on to one
A4 page. A number of amendments were suggested, but only three of these were suggested by more
than one participant and no suggestions were made by more than two participants. We therefore did not
make any substantial amendments to the form.
Research Ethics Committee approval was secured in advance for the main study. Personal data were not
collected during the pilot study but the protocol was amended to state that the NHS number would be
used in the pandemic study to allow linkage with data from the Office for National Statistics and the
Intensive Care National Audit and Research Centre. The Confidentiality Advisory Group of the Health
Research Authority granted approval for use of the NHS number in the pandemic study under Section 251
of the NHS Act 2006. Separate arrangements were made in Scotland and Northern Ireland. We secured
approvals from 41 separate English trusts (49 separate sites), one Welsh site, one Northern Irish site and
two Scottish sites.
Conclusions
An observational cohort study to identify the most accurate triage method for predicting severe illness
in emergency department attendees with suspected pandemic influenza has been set up and is ready to
activate in a pandemic. Clinician views of the standardised CAF were generally positive. We were able to
collect usable data using the standardised CAF, although problems of missing data may limit analysis and
the paucity of seasonal influenza cases limited our ability to fully test how case identification and data
collection will proceed in pandemic.
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Chapter 1 Background
Description of the health problem
An influenza pandemic has the potential to place a huge strain upon health services, particularly the
emergency care services, which may be exacerbated by staff sickness absence due to influenza. Prior to
the 2009 H1N1 influenza pandemic, the UK influenza pandemic contingency plan predicted around
750,000 excess emergency department attendances and 82,500 excess hospitalisations during a
pandemic.1 A more recent estimate suggested that a pandemic could result in 50% of the population
having some symptoms, of whom 30% would seek primary care and 1–4% would need hospital
admission.2 The Pandemic Influenza Advisory Committee subgroup on modelling have estimated a likely
clinical attack rate of 3–35% (worst-case scenario 50%), with 10–25% of these to have complications and
a peak demand in the worst-case scenario of 13% of the population being ill.3 Pandemic planning needs
to encompass a wide range of potential scenarios, but even projections at the less severe end of the
spectrum could cause substantial problems of overcrowding at emergency departments that are already
often working close to capacity. Methods of triage for patients presenting to the emergency department
with suspected pandemic influenza are therefore required and need to be fair, robust and reproducible.4
The term ‘triage’ is often used to describe a brief initial assessment in the emergency department to
determine patient order of priority in the queue to be seen. In this proposal we use the term ‘triage’
more broadly to include the full process of emergency department assessment, potentially including
investigations such as blood tests and X-rays, and apply it to decision-making regarding whether or not
the patient should be admitted and whether or not they should be referred for high dependency or
intensive care.
Emergency department triage methods need to accurately predict the individual patient’s risk of death
or severe illness. The predicted risk can then guide decision-making. Patients with a low risk may be
discharged home, those with a higher risk admitted to hospital, and those at highest risk referred for high
dependency or intensive care. The level of risk used to trigger these decisions need not necessarily be fixed
or determined in advance. Indeed, it is likely that decision-making thresholds could change during the
course of a pandemic, as the balance between resource availability and demand changes. Triage methods
that use a risk prediction score to determine the need for hospital care may therefore be more useful than
a triage rule that classifies patients into admission and discharge categories.
Current triage methods for pandemic influenza
Health Protection Agency (HPA) guidance prior to the 2009 pandemic, supported by the British Thoracic
Society and British Infection Society, recommended the use of the CURB-65 pneumonia score5 for
adults with suspected influenza-related pneumonia. This score uses five variables [confusion, urea level,
respiratory rate, blood pressure (BP) and age] to generate a score of between 0 and 5. Subsequent
Department of Health guidelines on surge capacity in a pandemic also considered use of a
physiological–social score [Pandemic Modified Early Warning Score (PMEWS)] for adults.6 This score
uses physiological variables, age, social factors, chronic disease and performance status to generate a
score of between 0 and 7. National guidance specific to the 2009 H1N1 influenza pandemic included a
swine flu hospital pathway for emergency department management of adults and children with seven
criteria; any one of which predicts increased risk and the need for hospital assessment.7
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Existing evidence
We used the autumn/winter phase of the 2009 H1N1 influenza pandemic in Sheffield and Manchester to
evaluate the discriminant value of three potential systems for triage of emergency department patients
with pandemic influenza: CURB-65, PMEWS and the swine flu hospital pathway.8,9 However, the pandemic
in these areas was less severe than predicted and only five patients of the cohort of 481 met our
predefined criteria for critical illness. Within this cohort, the discriminant value (c-statistic) of the three
systems for predicting critical illness was moderate {CURB-65 0.78 [95% confidence interval (CI) 0.58 to
0.99], PMEWS 0.77 (95% CI 0.55 to 0.99) and the swine flu hospital pathway 0.70 (95% CI 0.45 to
0.96)}. Their performance in predicting hospital admission was worse: CURB-65 0.65 (95% CI 0.54 to
0.76), PMEWS 0.76 (95% CI 0.66 to 0.86) and the swine flu hospital pathway 0.62 (95% CI 0.51 to 0.72).
These findings suggested that clinicians were not using the recommended triage methods when deciding
whether to admit or discharge patients, and raised concerns about the accuracy of these methods for
predicting adverse outcome.
Other research during the pandemic cast doubt on the utility of existing triage systems. The Swine Flu
Triage (SwiFT) study of patients admitted to critical care with H1N1 influenza found that 68% scored 0 or 1
using CURB-65 (i.e. recommended for hospital discharge).10 This is supported in evidence from a Canadian
seasonal flu cohort, for which no triage system performed well in predicting intensive care admission
[c-statistics PMEWS 0.63 (95% CI 0.57 to 0.69), CURB-65 0.58 (95% CI 0.52 to 0.64)].11 The best
discriminator in this cohort was SMART-COP, a system specifically developed to predict intensive care
admission in community-acquired pneumonia,12 which achieved a c-statistic of 0.73 (95% CI 0.67 to 0.79)
but has not to our knowledge been examined in a pandemic cohort. The SwiFT study10 also developed a new
score based on systolic BP, temperature, heart rate, respiratory rate, neurological status and inspired oxygen
concentration to predict adverse outcome. The SMART-COP and SwiFT scores therefore offer alternative
triage methods that require validation in a pandemic. Capelastegui et al.13 developed a score including age,
sex, comorbidities and clinical presentation, which had a c-statistic of 0.74 for predicting major complications,
but this has also not been validated in any external cohort.
A number of cohort studies were undertaken during the 2009 H1N1 influenza pandemic and in
subsequent flu seasons to identify risk factors for poor outcome in various groups.14–57 We have
systematically reviewed these studies and present the main findings in Appendix 1. The predominant
predictors of adverse outcome were chronic comorbidities and obesity, with conflicting evidence regarding
the risk of pregnancy. Acute physiological disturbances, particularly hypoxia, were also found to have
prognostic value.
The existing research therefore suggests that, although there are a number of patient characteristics and
clinical measures that can predict adverse outcome, the available data do not support the use of any
specific triage methods in suspected pandemic influenza.
BACKGROUND
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Chapter 2 Research questions
Further research is required to identify predictors of adverse outcome and develop triage methods foruse in pandemic influenza. Research in seasonal influenza and other respiratory illnesses can help
to inform triage methods for pandemic influenza, but differences in the clinical characteristics of different
respiratory illnesses and influenza strains mean that any triage method developed outside a pandemic
needs to be tested in a pandemic and, ideally, pandemic influenza triage methods should be developed or
refined during a pandemic.
The PAINTED (PAndemic INfluenza Triage in the Emergency Department) study has been planned to allow
rapid implementation of a research protocol in a pandemic affecting the UK NHS, which will identify the
most accurate triage method for predicting severe illness among patients attending the emergency
department with suspected pandemic influenza. Successful implementation of a research protocol in a
pandemic will require all regulatory approvals to be secured in advance, piloting of data collection
processes, regular updating of the protocol, and plans for protocol activation. This report describes the
PAINTED protocol, the results of piloting the protocol, and the plans for protocol updating and activation
in the event of a pandemic.
The aim of the PAINTED study is to identify the most accurate triage method for predicting severe illness
among patients with suspected pandemic influenza who are attending the emergency department.
The specific objectives are to:
1. determine the discriminant value of emergency department triage methods for predicting severe illness
in patients presenting with suspected pandemic influenza
2. determine the discriminant value of presenting clinical characteristics and routine tests for identifying
severe illness
3. determine the independent predictive value of presenting clinical characteristics and routine tests for
severe illness
4. develop two new triage methods based upon (1) presenting clinical characteristics alone and
(2) presenting clinical characteristics, electrocardiogram (ECG), chest X-ray (CXR), and routine blood
test results.
The aim of the pilot study was to test the PAINTED study methods during a winter influenza season.
The specific objectives were to:
1. develop and test the use of a standardised clinical assessment form (CAF) that could be used for both
clinical record documentation and research data collection during a pandemic
2. develop and test a secure online database to allow efficient data management in a pandemic
3. analyse pilot data from patients with seasonal influenza to ensure that data are reasonably complete
and within expected ranges
4. seek clinician views on the usability of the standardised CAF
5. obtain all regulatory approvals required for the main study so that it can be activated rapidly in the
event of a pandemic.
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Chapter 3 Methods
The PAINTED study will be a prospective observational cohort study of patients attending the emergencydepartment with suspected pandemic influenza, which aims to develop and evaluate triage methods
for identifying those at risk of serious adverse outcome. It will evaluate triage methods used to determine
whether or not a patient with suspected pandemic influenza should be admitted to hospital or not, and
whether or not they should be admitted to intensive or high dependency care. These will include the
CURB-65 score, PMEWS, the swine flu hospital pathway, SMART-COP, the SwiFT score and any new
methods developed before the next pandemic. It will also develop two new triage methods based upon
presenting (1) clinical characteristics alone and (2) clinical characteristics, ECG, CXR and routine blood
test results.
The first score will use only variables that are available at initial patient assessment, i.e. history and
examination, including simple technologies, such as automated BP measurement and pulse oximetry.
This triage method can be used to assess patients for the need for hospital investigation and identify
patients who can be discharged without further assessment. It could potentially be used, with appropriate
validation, to assess patients in the community.
The second triage method will be based upon all available emergency department data, including
routine blood tests, ECG and CXR findings. This triage method can be used for two potential purposes:
identification of (1) patients with a low risk of adverse outcome who can be discharged home after
emergency department assessment; and (2) high-risk patients who are likely to need high dependency or
intensive care.
The PAINTED study will evaluate the ability of each method to predict whether patients die or require
respiratory, cardiac or renal support. We will not evaluate the impact of triage methods upon patient care.
Intervention in the study will therefore consist of only data collection and follow-up. Patient management
will continue according to whatever national guidance is in place at the time of the pandemic.
We will initially aim to develop triage methods that can be applied to the whole population of patients
presenting to the emergency department. Age-dependent variables will be assessed and included in the
triage method in relation to age-specific normal ranges. We will then explore whether different triage
methods may be appropriate for different patients, particularly whether or not a different triage method
may be appropriate for children.
Full details of the PAINTED study are provided in the PAINTED protocol (see Appendix 2). This chapter
describes the pilot study methods.
The PAndemic INfluenza Triage in the Emergency Department
pilot study
The PAINTED pilot study involved using the standardised CAF and online database to collect data from
patients presenting to the emergency department with suspected seasonal influenza, thus testing
processes planned for the PAINTED study in the event of a pandemic.
A standardised CAF was developed, which was intended to double as clinical notes and study data
collection form. It was based on the form used in our 2009 pandemic influenza study,9 and was
designed to be easy for clinical staff to complete and include the key information required for clinical
record-keeping. It also included the elements of all currently available triage methods, variables identified
in previous studies as being predictors of adverse outcome (see Appendix 1), any other potential predictors
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that are routinely recorded in the emergency department (comorbidities, physiological observations,
routine blood tests, ECG and CXR), and details of any pre-presentation antiviral medication, antibiotics and
immunisation status. The form is reproduced in Appendix 3.
The pilot study was undertaken during winter 2012–13 across six acute hospitals: the Northern General
Hospital (Sheffield), Sheffield Children’s Hospital, Salford Royal Hospital (Greater Manchester), York Hospital,
Scarborough Hospital and The Royal London Hospital. We included all adults and children presenting with
suspected influenza at the emergency departments of the participating hospitals. Patients were eligible for
inclusion if they met the current clinical diagnostic criteria of (1) fever (pyrexia ≥ 38 °C) or a history of fever
and (2) influenza-like illness (two or more of cough, sore throat, rhinorrhoea, limb or joint pain, headache,
vomiting or diarrhoea) or a severe and/or life-threatening illness that is suggestive of an infectious process.
The assessing clinician determined eligibility and completed the standardised CAF if the patient was
considered to have suspected influenza. Research nurses employed by each hospital then photocopied the
form, secured the original form in the notes and took the copy away.
Patients were followed up until 30 days after attendance by hospital record review to identify adverse
outcomes. Patients who died or required respiratory, cardiovascular or renal support were defined as
having an adverse outcome. If they survived to 30 days without requiring respiratory, cardiovascular or
renal support they were defined as having no adverse outcome. We also recorded whether or not they
were treated with antiviral agents or antibiotics, and the length and location of any hospital stay.
Respiratory support was defined as any intervention used to protect the patient’s airway or assist their
ventilation, including non-invasive ventilation or acute administration of continuous positive airway
pressure. It did not include supplemental oxygen alone or nebulised bronchodilators. Cardiovascular
support was defined as any intervention used to maintain organ perfusion, such as inotropic drugs, or
invasively monitor cardiovascular status, such as central venous pressure or pulmonary artery pressure
monitoring, or arterial BP monitoring. It did not include peripheral intravenous canulation and/or fluid
administration. Renal support was defined as any intervention used to assist renal function, such as
haemoperfusion, haemodialysis or peritoneal dialysis. It did not include intravenous fluid administration.
Outcome assessment was based primarily on research nurse review of hospital computer records and case
notes. The hospital computer records were checked at least 30 days after presentation for death or
hospital admissions. If the patient was alive at 30 days, was discharged home from the emergency
department and did not reattend hospital they were recorded as having no adverse outcome. If they died,
were admitted to hospital or reattended hospital within 30 days, their hospital notes were retrieved and
reviewed by the research nurse. If there was no evidence in the hospital notes of an adverse outcome the
patient was recorded as having no adverse outcome.
The research nurse recorded details of adverse events on a follow-up form. Once complete, the research
nurse entered all non-personal data on to a secure online database provided by the Sheffield Clinical Trials
Research Unit (CTRU). Personal details (date of birth, NHS number, hospital number and emergency
department number) were accessed by the research nurses to allow linkage back to source data but were
not accessible to research staff in Sheffield. A unique study number provided a common identifier for
research nurses and CTRU researchers. The research nurses kept a record of any patient who withdrew
from the project but did not communicate details to other staff.
We intended to collect data from around 400 cases for the pilot study, with each pilot site collecting data
from 60 to 80 cases. We estimated that this would provide sufficient numbers to test data collection and
management, and to explore missing data rates. The main purpose of the pilot phase was to test data
completion rates and the processes for data abstraction and reporting, so only descriptive data analysis
was undertaken.
METHODS
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The standardised CAF was evaluated for acceptability and usability through 12 semistructured interviews
with emergency department doctors and nurse practitioners based at four of the pilot sites. Participants
were purposively sampled on the basis of having had experience of using the form during the pilot phase.
Those who had no experience of using the form were provided with a copy of the form and its guidance
to review prior to the interview. The interviews were undertaken by a single researcher (DB) as part of
an educational project. The researcher was not otherwise involved in the PAINTED project but was
supervised by members of the research team (SG, AI, RW). The interview schedule is reproduced in
Appendix 4. Data were analysed using a framework approach.58
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Chapter 4 Ethical and governance processes and
pandemic study site set-up
An essential part of the pilot study involved identifying and addressing the ethical and governanceprocesses that needed to be in place in advance of the main pandemic study. We intended to
undertake the pilot study using the same protocol as the main pandemic study to ensure that ethical and
governance issues were addressed in the pilot study, so that all necessary approvals were in place in
advance of a pandemic.
Ethical issues
The pilot study did not alter patient management and neither will the pandemic study. Both simply involve
collecting routinely available data at presentation and follow-up. No additional diagnostic tests are
performed. The risks to patients involved in the study are therefore very low and principally relate to data
protection and confidentiality.
In accordance with plans for the main study, posters were prominently displayed in all participating
departments, advising patients of the project and providing contact details for further information. Leaflets
that briefly described the nature and purpose of the study (see Appendix 5) were provided for staff to
hand to patients with suspected influenza and to provide contact details for further information.
We did not seek patient consent to participate on the basis that the study was limited to collection
of routinely available data and any delays in patient assessment would risk compromising patient care.
The information leaflet provided a tear-off slip with contact details that patients could use to inform
the hospital or research team if they wished to withdraw from the study. Patients who wished to
withdraw from the study would have their study records deleted. Their decision to withdraw would
not be communicated to clinical staff providing further care and would not influence their
subsequent management.
In our previous pandemic study,9 we obtained approval from the National Information Governance Board
(NIGB) to collect personal data without patient consent under Section 251 of the NHS Act 2006.59 We
intended to do the same in the pilot and pandemic phases of PAINTED. However, the Ethics and
Confidentiality Committee (ECC) of the NIGB ruled that they were unable to (1) approve our use – during
the pilot phase, in the absence of a pandemic – of certain items of identifiable information without
informed consent and (2) give a decision concerning the main phase of the study, partly because of
uncertainty regarding possible changes to the common law duty of confidentiality, and partly because of
the imminent dissolution of the ECC itself. We felt that requesting consent would make the pilot study too
different from the pandemic study for it to be a meaningful pilot of the processes involved. We therefore
decided to remove all personal details from the data set during the pilot phase so that data could be
collected without patient consent. Following this amendment, Research Ethics Committee (REC) approval
was granted by the North West (Haydock) REC without the need for Section 251 approval.
Responsibility for Section 251 approval subsequently passed from the NIGB to the Confidentiality Advisory
Group (CAG) of the Health Research Authority. We therefore submitted to the CAG an application for
Section 251 approval for the pandemic phase of the project, together with a concomitant ‘notice of
amendment’ to the REC. We were granted Section 251 conditional approval contingent upon satisfying
certain conditions. REC approval for the pandemic study was granted, conditional upon Section 251
approval. Initially, correspondence with the NIGB questioned the need for an application at this point,
advising that it may be best to wait until a pandemic situation arose. It was necessary to clarify that the
nature of the funding award specified the expectation to seek regulatory approvals in readiness of a
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pandemic. Despite this, the NIGB maintained obvious concerns over the timing of a future pandemic and
the legal and regulatory landscape that may exist at that time.
The main condition for approval was to satisfy (to the mandatory level) each of the 14 requirements of
the Information Governance Toolkit assessment, including technical data security, standard operating
procedures, information governance staff training and human resource contractual matters beyond the
responsibility of the research team. Completing the Toolkit on a per-project basis appears to be a very
cumbersome and inefficient way to operate, placing a significant burden on the resources of research
teams. Both the initial application and yearly review represent a significant burden, which may damage the
long-term viability of maintaining a pandemic study in long-term ‘hibernation’. The University of Sheffield
[specifically the School of Health and Related Research (ScHARR)] has therefore appointed an information
governance lead to develop an information governance policy that addresses the requirements of the
Toolkit and will be maintained to demonstrate an ongoing institutional level commitment to adequate
standards of information handling and security.
The study protocol now states that the only patient-identifiable information recorded on to the database
and viewable by the research team will be NHS numbers. These will be used to cross-check the
completeness of the data set by comparing NHS numbers with the Intensive Care National Audit and
Research Centre (ICNARC) database and the Office for National Statistics (ONS). The cross-check with
ICNARC will be to determine that our data set has captured all intensive care usage and associated adverse
outcomes. Should there be cases in the ICNARC database that are not present in the PAINTED database,
we would endeavour to retrieve the missing clinical data (linking the cases via the NHS number) to
supplement the PAINTED data set. Capturing missing mortality data will be undertaken via a search
organised by the ONS. Linking of records would again be made using the NHS number.
The qualitative interview study did not involve patients, so NHS REC approval was not sought. Instead,
the study was approved by the University of Sheffield (ScHARR) REC.
Research governance
Sheffield Teaching Hospitals NHS Foundation Trust was the pilot study sponsor and will be sponsor for the
main pandemic study. The pilot was managed by staff in the section of Health Services Research in
ScHARR in the University of Sheffield: Steve Goodacre (Chief Investigator), Mike Campbell (Statistician),
Andrew Lee (Public Health), Richard Wilson (Project Manager), Andy Irving (Research Associate),
Kirsty Challen (Postgraduate Research Student) and Kathryn MacKellar (Administrator). Responsibility has
now passed to the Sheffield CTRU (also based in ScHARR) but the Chief Investigator and project team
remain essentially unchanged. The project management group met quarterly between March 2012 and
September 2013, when the study was placed in hibernation. Yearly review meetings were scheduled
from October 2014 to ensure that the study maintained its readiness in the event of a pandemic.
A Steering Committee was formed to oversee study progress. The committee included Timothy Coats
(Chair, Professor of Emergency Medicine), Jonathan Van Tam (Professor of Health Protection), Paul Baxter
(Senior Lecturer in Biostatistics), Stephen Morton (Regional Director of the HPA Yorkshire and the Humber),
Lynn Winspear [Sheffield Emergency Care Forum (SECF), Patient and Public Representation], Enid Hirst
(SECF), Steve Goodacre and Richard Wilson. Lynn Winspear, Enid Hirst and other members of SECF also
provided specific input into the project’s lay summary and patient leaflets.
ETHICAL AND GOVERNANCE PROCESSES AND PANDEMIC STUDY SITE SET-UP
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Regulatory approvals for the pandemic phase
The pandemic phase aims to collect data from 20,000 patients presenting with suspected pandemic
influenza across 40 sites. We planned to identify sites and principal investigators, establish processes and
obtain research governance approvals at these sites during the pilot phase. We aimed to recruit sites across
the whole of the UK to ensure that we would not miss the early phases of a pandemic localised to a
particular geographical area.
We secured approvals from 41 separate English trusts (49 separate sites), one Welsh site, one Northern
Irish site and two Scottish sites. The sites are listed in Table 1, below.
TABLE 1 Sites recruited for the pandemic phase
No. Hospital site NHS trust
1 Northern General Hospital Sheffield Teaching Hospitals NHS Foundation Trust
2 Sheffield Children’s Hospital Sheffield Children’s NHS Foundation Trust
3 Salford Royal Hospital Salford Royal Hospital NHS Foundation Trust
4 York District Hospital York Teaching Hospital NHS Foundation Trust
5 Scarborough General Hospital York Teaching Hospital NHS Foundation Trust
6 The Royal London Hospital Bart’s and The London NHS Trust
7 Wythenshawe Hospital University Hospital of South Manchester NHS Foundation Trust
8 Barnsley Hospital Barnsley Hospital NHS Foundation Trust
9 Poole Hospital Poole Hospital NHS Foundation Trust
10 Northampton General Hospital Northampton General Hospital NHS Trust
11 Hull Royal Infirmary Hull and East Yorkshire Hospitals NHS Trust
12 Bristol Royal Infirmary University Hospitals Bristol NHS Foundation Trust
13 Derriford Hospital Plymouth Hospitals NHS Trust
14 Milton Keynes Hospital Milton Keynes Hospital NHS Foundation Trust
15 Royal Berkshire Hospital Royal Berkshire NHS Foundation Trust
16 Arrowe Park Hospital Wirral University Teaching Hospital NHS Foundation Trust
17 Cumberland Infirmary North Cumbria University Hospitals NHS Trust
18 West Cumberland Hospital North Cumbria University Hospitals NHS Trust
19 Dorset County Hospital Dorset County Hospital NHS Foundation Trust
20 Gloucestershire Royal Infirmary Gloucestershire Hospitals NHS Foundation Trust
21 King’s Mill Hospital Sherwood Forest Hospitals NHS Foundation Trust
22 New Cross Hospital The Royal Wolverhampton Hospitals NHS Trust
23 The Princess Royal Hospital Shrewsbury And Telford Hospital NHS Trust
24 Wansbeck Hospital Northumbria Healthcare NHS Foundation Trust
25 Doncaster Royal Infirmary Doncaster and Bassetlaw Hospitals NHS Foundation Trust
26 University Hospital North Staffordshire University Hospital of North Staffordshire NHS Trust
27 Southend Hospital Southend University Hospital NHS Foundation Trust
28 John Radcliffe Infirmary Oxford Radcliffe Hospitals NHS Trust
continued
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Recruitment of Northern Irish and, in particular, Scottish sites involved a disproportionate amount of
additional preparatory work. We briefly outline the issues here for the benefit of researchers planning
similar studies across the devolved nations. Section 251 approval does not provide a lawful means to
collect patient-identifiable information without consent in Northern Ireland or Scotland. Furthermore,
research using data from incapacitated adults in Scotland requires informed consent to participate, either
directly from the person concerned or indirectly via a relative or a welfare guardian. In Northern Ireland we
had to provide an alternative assurance of good information handling, data protection systems and
processes, which consisted of an 18-page ‘data access agreement’ to the trust Caldicott Guardian.
In Scotland, we were advised that PAINTED should be undertaken as an audit and, as such, we would be
able to collect identifiable patient data from all categories of patient without any restrictions. This involved
a new national governance application, development of a new bespoke local site contract process, and
submission of a 48-page application for Privacy Advisory Committee (PAC) approval for the collection of
patient identifiers, namely the date of birth and Community Health Index number (analogous to the NHS
number). Like the Information Governance Toolkit assessment, the PAC application required extensive
input from multiple stakeholders, including technical electronic data flow and data protection protocols,
various standard operating procedures and information governance training.
TABLE 1 Sites recruited for the pandemic phase (continued )
No. Hospital site NHS trust
29 Harrogate District General Hospital Harrogate and District NHS Foundation Trust
30 Broomfield Hospital Mid Essex Hospital Services NHS Trust
31 Royal Victoria Infirmary The Newcastle Upon Tyne Hospitals NHS Foundation Trust
32 Manchester Royal Infirmary Central Manchester University Hospitals NHS Foundation Trust
33 Royal Manchester Children’s Hospital Central Manchester University Hospitals NHS Foundation Trust
34 Aintree University Hospital Aintree University Hospitals NHS Foundation Trust
35 Coventry and Warwickshire University Hospital University Hospitals Coventry and Warwickshire NHS Trust
36 Addenbrooke’s Hospital Cambridge University Hospitals NHS Foundation Trust
37 Queen’s Medical Centre Nottingham University Hospitals NHS Trust
38 Royal Lancaster Infirmary University Hospitals of Morecambe Bay NHS Foundation Trust
39 Furness General Infirmary University Hospitals of Morecambe Bay NHS Foundation Trust
40 Wexham Park Hospital Heatherwood And Wexham Park Hospitals NHS Foundation Trust
41 Queen Elizabeth Hospital The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust
42 Great Western Hospital Great Western Hospitals NHS Foundation Trust
43 Royal United Hospital Royal United Hospital Bath NHS Trust
44 King’s College Hospital King’s College Hospital NHS Foundation Trust
45 Ashford and St Peter’s Hospital Ashford and St Peter’s NHS Foundation Trust
46 Royal Gwent Hospital, Wales Aneurin Bevan Health Board
47 Craigavon Area Hospital, Northern Ireland Southern Health and Social Care Trust
48 Edinburgh Royal Infirmary, Scotland NHS Lothian
49 Royal Alexandra Hospital, Scotland NHS Greater Glasgow and Clyde
ETHICAL AND GOVERNANCE PROCESSES AND PANDEMIC STUDY SITE SET-UP
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In addition to approval from the PAC, we were advised that we required specific additional approvals to
collect Community Health Index numbers, addressed via a Caldicott Guardian National Scrutiny Process.
This National Caldicott Forum advised that we would need to retain the use of patient information sheets
and study posters (as per protocol) to inform patients of the use of their data and provide means to
withdraw their data if requested. However, we were informed by the National Records of Scotland that
the use of patient data for audit is routine in Scottish hospitals, so the use of information sheets or posters
would be inappropriate. We have established that, by directing each organisation to the other’s advice,
authority lies with the National Caldicott Forum and we retain the use of these study documents in
Scottish sites.
We created a Scottish-specific protocol to reflect implementation of PAINTED as an audit in Scotland,
highlighting deviations in operating procedures from the rest of the UK. We sought advice from the
English REC with regard to these matters and received favourable opinion to proceed as advised
in Scotland.
In summary, we were able to set up sites across the whole of the UK in advance of the pandemic phase of
PAINTED, but found that navigating divergent – and sometimes incongruent – ethical and governance
frameworks resulted in a disproportionate amount of resources being committed to, including sites in the
devolved nationals (particularly Scotland), which may have impaired our ability to include non-English sites.
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Chapter 5 Pilot study results
The pilot study was undertaken across six hospitals in winter 2012–13. Table 2 shows the start and enddates for case identification at the participating hospitals. Recruitment at the Northern General Hospital
was extended for 1 month in an attempt to identify more patients but without success.
There were low levels of seasonal influenza overall during winter 2012–13, with consultations for
influenza-like illness peaking at 30.1 per 100,000.60 As a result, we were unable to achieve our target of
collecting data from 400 cases. Overall, 165 patients with suspected influenza were identified across the
six participating hospitals and had CAFs completed. Ten patients subsequently withdrew their data from
the study, leaving 155 (94%) available for analysis. Follow-up data were available from 129 of 155
patients at 30 days (83%). Of these, 50 of 129 (39%) were admitted to hospital and 3 of 129 (2%)
suffered an adverse outcome. Figure 1 illustrates the flow of patients through the pilot study.
TABLE 2 Recruitment dates and numbers across the participating hospitals
Recruitment
milestone
Sheffield
Children’s
Hospital
Salford
Royal
Hospital
Royal
London
Hospital
Northern
General
Hospital
York
District
General
Scarborough
General Hospital
Recruitment
starta
14 November
2012
20 September
2012
13 November
2012
8 October
2012
5 November
2012
29 January 2013
Recruitment
end
31 March
2013
31 March
2013
31 March
2013
26 April
2013
31 March
2013
31 March 2013
Recruitment
days
137 191 138 198 146 62
Patients
recruited
36 50 64 2 11 2
a Taken as the date when NHS permission was granted or the research contract fully signed, whichever is latest.
79 discharged 50 admitted
165 cases identified 10 withdraw 
155 provided data 26 lost to follow-up 
129 followed up 
47 survived 
3 died 
FIGURE 1 Flow of patients through the pilot study.
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Table 3 shows patient flow by hospital. Three of the hospitals identified 150 of 165 (91%) of the patients.
This suggests that either seasonal influenza incidence was very low at the other three hospitals or these
hospitals were failing to identify cases for the study. All 10 withdrawing patients were at the same
hospital. Reasons for withdrawal were not requested from patients, so we are unable to draw any further
conclusions regarding withdrawals. All three of the hospitals with meaningful patient numbers were
unable to collect follow-up data from a proportion of cases, with proportions ranging from 8% to 31%.
Admission rates varied substantially, even allowing for small numbers, from 4% to 85% across the
hospitals reporting meaningful numbers of cases. All of the deaths were at one hospital. Although we
should be careful about drawing conclusions from these small numbers, they suggest a substantial degree
of variation between hospitals in rates of case identification, withdrawal, follow-up and hospital admission.
Table 4 shows data completion for key variables on the case report form by hospital and across all
hospitals. BP is usually measured in children only if they are severely ill. This explains why recording of BP is
so low at Sheffield Children’s Hospital.
The mean age of the cohort was 31 years (median 26.5 years, range 1–92 years), with 49 of 127 (39%)
aged 0–16 years. There were 72 males and 71 females. The referral source among those with usable data
for this variable was self-referral for 114 (80%), general practitioner (GP) for nine (6%), multiple for six
(4%) and other for 14 (10%). Mean symptom duration was 5.6 days (median 3 days, range 1–56 days).
Performance status among those with usable data for this variable was unrestricted/normal in 78 (67%),
limited by strenuous activity in seven (6%), limited by non-strenuous activity in 25 (21%), limited by
self-care in five (4%) and bed-/chair-bound in two (2%).
Table 5 reports descriptive statistics for physiological variables. Elevated temperature, heart rate and
respiratory rate are all in keeping with acute febrile illness. Capillary refill was normal in 55 patients and
not recorded in 100 patients. The modal values for eyes, Glasgow Coma Scale (GCS) verbal and GCS
motor component scores were 4, 5 and 6, respectively. The alert, verbally responsive, responsive to pain or
unconscious (AVPU) response scale was recorded as alert in all 109 cases in which it was recorded.
A CXR was normal in 28, abnormal in 23 and not undertaken in 67 of the 118 cases with details
recorded. ECG was normal in 26 patients, abnormal in 14 and not undertaken in 71 of the 111 cases
with ECG details recorded.
Social isolation and eight chronic diseases were recorded as being present by ticking a box, so it was not
possible to determine whether no tick in the box indicated absence of the variable or missing data.
Social isolation (defined as living alone or having no fixed abode) was reported by 27 patients (16%).
TABLE 3 Patient flow through the study by site
Patient
nos.
Sheffield
Children’s
Hospital
Salford
Royal
Hospital
Royal
London
Hospital
Northern
General
Hospital
York
District
General
Scarborough
General
Hospital
All
hospitals
Total 36 50 64 2 11 2 165
Withdrawn 0 0 10 (16%) 0 0 0 10 (6%)
Data
available
36 (100%) 50 (100%) 54 (84%) 2 (100%) 11 (100%) 2 (100%) 155 (94%)
30-day
follow-up
completed
25 (69%) 46 (92%) 45 (83%) 0 11 (100%) 2 (100%) 129 (83%)
Admitted 1 (4%) 39 (85%) 7 (16%) 0 2 (18%) 1 (50%) 50 (39%)
Deaths 0 3 (8%) 0 0 0 0 3 (2%)
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TABLE 4 Data completion for key variables by hospital and across all hospitals
Variable
Sheffield
Children’s
Hospital
Salford
Royal
Hospital
Royal
London
Hospital
Northern
General
Hospital
York
District
General
Scarborough
General
Hospital
All
hospitals
No. 36 50 54 2 11 2 155
Age 34 (94%) 48 (96%) 30 (56%) 2 (100%) 11 (100%) 2 (100%) 127 (82%)
Sex 36 (100%) 48 (96%) 44 (81%) 2 (100%) 11 (100%) 2 (100%) 143 (92%)
Referral
source
34 (94%) 43 (86%) 51 (94%) 2 (100%) 11 (100%) 2 (100%) 143 (92%)
Performance
status
16 (44%) 43 (86%) 45 (83%) 2 (10%) 10 (91%) 1 (50%) 117 (75%)
Symptom
duration
33 (92%) 39 (78%) 47 (87%) 1 (50%) 10 (91%) 2 (100%) 132 (85%)
Temperature 34 (94%) 47 (94%) 52 (96%) 2 (100%) 11 (100%) 2 (100%) 148 (95%)
Pulse rate 35 (97%) 45 (90%) 51 (94%) 2 (100%) 10 (91%) 1 (50%) 144 (93%)
Respiratory
rate
36 (100%) 48 (96%) 50 (93%) 2 (100%) 11 (100%) 1 (50%) 148 (95%)
BP 1 (3%) 34 (68%) 49 (91%) 2 (100%) 8 (73%) 0 94 (61%)
Oxygen
saturation
27 (75%) 45 (90%) 50 (93%) 2 (100%) 10 (91%) 1 (50%) 135 (87%)
Inspired
oxygen
14 (39%) 41 (82%) 29 (54%) 1 (50%) 3 (27%) 0 88 (57%)
Capillary refill 31 (86%) 17 (34%) 40 (74%) 2 (100%) 9 (82%) 1 (50%) 100 (64%)
GCS 11 (31%) 30 (60%) 39 (72%) 2 (100%) 7 (64%) 0 89 (57%)
AVPU 25 (69%) 44 (88%) 35 (65%) 2 (100%) 2 (18%) 1 (50%) 109 (70%)
CXR 33 (92%) 35 (70%) 36 (67%) 2 (100%) 11 (100%) 1 (50%) 118 (76%)
ECG 33 (92%) 27 (54%) 38 (70%) 1 (50%) 11 (100%) 1 (50%) 111 (72%)
TABLE 5 Descriptive statistics for physiological variables
Variable n Mean (SD) Range
Temperature (°C) 148 37.8 (1.0) 35.9–40.0
Pulse rate (per minute) 144 108 (28) 59–180
Respiratory rate (per minute) 148 25 (10) 13–60
Systolic BP (mmHg) 94 124 (23) 71–203
Diastolic BP (mmHg) 94 71 (13) 41–108
Oxygen saturation (%) 135 96 (3) 83–100
SD, standard deviation.
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Chronic diseases were recorded with the following frequencies: heart disease, 18; renal impairment, six;
steroid therapy, one; asthma, 17; other chronic lung disease, 14; diabetes, nine; active malignancy, one;
and immunosuppression, one.
Influenza was thought by the clinician to be the most likely diagnosis in 34 of 155 cases (22%). The most
common alternatives were upper respiratory tract infection (17 cases), community-acquired pneumonia
(11 cases) and lower respiratory tract infection (five cases).
Blood test results were available for 32 of 155 cases. Table 6 reports descriptive statistics for blood
variables. Results were generally within normal ranges, with the exception of white cell count (WCC),
which tended to be elevated in keeping with acute infective illness.
Follow-up data were available from 129 of 155 attendances. Table 7 shows the number of admissions
across the centres with length of stay for the two hospitals with meaningful numbers of admissions.
Overall, 50 of 129 patients were admitted with a mean length of stay of 3.9 days (median 2 days,
range 0–22 days).
TABLE 6 Descriptive statistics for blood variables
Variable n Mean (SD) Range
Haemoglobin (g/dl) 32 13.5 (1.9) 9.5–16.0
WCC (× 109/l) 10.1 (4.2) 4–18
Platelet count (× 109/l) 234 (112) 132–606
Sodium (mmol/l) 138 (4) 125–145
Potassium (mmol/l) 3.9 (0.6) 3.0–5.9
Urea (mmol/l) 6.2 (6.6) 2.3–29.2
Creatinine (µmol/l) 87 (55) 47–370
SD, standard deviation.
TABLE 7 Number of admissions and length of stay by hospital
Parameter
Sheffield
Children’s
Hospital
Salford
Royal
Hospital
Royal
London
Hospital
Northern
General
Hospital
York
District
General
Scarborough
General
Hospital
All
hospitals
No. of
admissions
1 39 7 0 2 1 50
LoS recorded 1 38 7 0 2 1 49
Mean LoS – 4.2 3.3 – – – 3.9
Median LoS – 2 3 – – – 2
Range – 0–22 0–9 – – – 0–22
LoS, length of stay (days).
PILOT STUDY RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Three cases were recorded as having suffered an adverse outcome. All three died; two also received
respiratory, cardiovascular and/or renal support. Details are as follows:
1. Female, aged 31 years, died after receiving extracorporeal membrane oxygenation, and respiratory,
cardiovascular and renal support.
2. Male, aged 83 years, died after receiving respiratory and cardiovascular support.
3. Male, aged 87 years, died with no record of having received respiratory, cardiovascular or renal support.
Clinician views on the standardised clinical assessment form
Most participants believed that the content of the form was both appropriate and useful, although its
adult-centric nature was noted by some. At the very least, they felt that it included the minimum level of
information required in dealing with a case of pandemic flu, but elements of added value were noted,
such as allowing for, and prompting, the documentation of a thorough history and examination. Some
individuals noted that elements of the form were either unclear in terms of what they required or would
benefit from greater detail, with suggestions for specific pointers in the ‘Clinical examination’ section and
space to document details of abnormal findings.
The structure of the form was received well in terms of ease of use owing to its clarity, simplicity and
concise nature. It was felt to be logical, with some participants commenting that it mirrored their own
practice of taking notes. Despite positive reflections on the fact that the form fitted on to one A4 page,
a greater number of those interviewed felt that it did not have enough space for them to write all of the
free text that they would like.
A number of amendments to the form were suggested and are outlined in Table 8. There was little
consistency across the participants in the amendments suggested, and the majority of suggestions were
made by only single participants. Three suggestions were made independently by two participants.
These were to reduce the size of the ‘Patient criteria’ and ‘Performance status’ sections, and to move the
observations box to the top of the second page. Most participants favoured an electronic rather than
paper version of the form, as they considered that it would be quicker, although it should be noted that
the majority of those interviewed had experience of using the latter during the pilot phase.
In terms of the purpose of the form, the majority of participants considered it to be a helpful clinical record
and, almost without exception, felt that, putting aside their experience during the pilot, they would be
confident using it in a future pandemic situation with the accompanying guidance. Indeed, one participant
noted that his/her unit felt that it would be useful enough to continue using after the pilot had ended.
However, some of those interviewed commented that it lacked use beyond data collection in terms of
assisting in the patient management process, and one person commented that the condition-specific
design of the form meant that it could direct health-care professionals towards a wrong diagnosis.
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TABLE 8 Suggested amendments to the standardised CAF
Form content
Include space to provide details about abnormal central
capillary refill, CXR or ECG findings
Include specific pointers in the ‘Clinical examination’
section, detailing what clinicians should be looking for
Use of a separate paediatric form Suggested by two participants, although acknowledged by
one to be difficult to implement practically in a department
seeing all ages
Form structure
Reduce the size of the ‘Patient criteria’ and ‘Performance
status’ sections
Suggested by two participants
Move the observations box to the top of the second page Suggested by two participants
Relocate the title to the top of the form
Combine the ‘Past medical history’ and ‘Chronic
disease’ sections
Reduce the size of the ‘Referral source’ section
Combine the ‘Previous’, ‘Antibiotic therapy?’ and ‘Symptom
duration’ sections
Increase the size of the ‘Current medication’ section
Relocate the ‘Clinically obese?’ and ‘Pregnant?’ questions
to somewhere more appropriate
With the observations box at the top of the page, move the
‘Investigations’ section after ‘Clinical examination’ (which
should include the ‘Severe respiratory distress’ and
‘Respiratory exhaustion’ questions), followed by a renamed
‘Differential diagnosis including other clinical concerns’
Split the ‘Clinical examination’ section to include specific
respiratory examination information
Note
All suggestions were made by only one participant unless specifically noted.
PILOT STUDY RESULTS
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Chapter 6 Discussion
We developed a standardised CAF that was used for both clinical record documentation and researchdata collection. Also, we developed a secure online database and used it to collect usable data from
participating hospitals. Interviews with clinicians revealed generally positive views on the standardised form
and willingness to use the form in the event of a pandemic. A number of amendments were suggested
but none was made by more than two participants. As a consequence, no substantial amendments were
made to the form. All regulatory approvals were obtained for the main study to allow it to be activated
rapidly in the event of a pandemic.
The pilot study was limited by the low incidence of influenza in the winter of 2012–13, which made it
difficult to draw conclusions about case identification and generalise these conclusions to a pandemic.
The variation in numbers of cases identified between the hospitals suggests that some hospitals were
failing to identify eligible cases for the study. However, this may reflect the difficulties of achieving staff
engagement when the incidence of cases is low and influenza is a low priority. Staff awareness and
engagement is likely to be much higher during a pandemic, although other challenges are likely to arise in
a pandemic that may compromise study progress in other unpredictable ways.
The pilot study also highlighted potential concerns about missing data, with data completeness varying
between items and between hospitals. Data were relatively complete for heart rate, respiratory rate,
temperature and peripheral oxygen saturation. They were lower for capillary refill, inspired oxygen, BP,
GCS score and AVPU. This is probably because patients who are well do not routinely have capillary refill
checked or receive supplementary oxygen, and children do not usually have their BP measured. The GCS
score is probably assumed to be 15/15 and AVPU response= ‘alert’ and thus not recorded in patients who
are well and able to provide a full history. When recorded, capillary refill was always normal, AVPU was
always ‘alert’ and GCS score was mostly 15.
Chest X-rays were performed in 51 of 118 cases, with details recorded, and ECGs were performed in
40 of 111 cases, with details recorded, whereas blood tests were recorded for 32 of 155 patients.
These low rates are unsurprising, as CXR, ECG and blood tests have a limited role in the assessment of
patients with uncomplicated influenza. It would be reasonable to assume that those without investigations
would have had normal investigations had they been performed, but the proportion of patients with no
record of whether or not the investigation was performed highlights the importance of improving
recording of this variable.
The primary analysis for the pandemic study will impute missing predictor variable data as being normal on
the assumption that the most likely reason for it being missing is that the clinician did not feel that it was
worth recording a variable or doing an investigation that was expected to be normal. However, this
assumption may not hold in a pandemic if clinical resources are overstretched. We have therefore planned
sensitivity analysis based on different imputation assumptions to test the assumption that missing values
are normal.
The adverse event rate was 3 of 129 cases (2%), which is similar to that observed in our 2009 H1N1
influenza pandemic study9 and suggests that our assumption of a low adverse event rate in sample size
calculation is appropriate.
Variation in missing data rates between hospitals is concerning, as it suggests that some hospitals were not
recording potentially available data. Deliberately, we did not use the opportunity afforded by the pilot
study to undertake rigorous chasing of missing data but instead used the light touch approach that is likely
to be the only feasible approach in a pandemic. We are involved in ongoing efforts to identify why specific
data items were missing at specific hospitals to determine whether or not processes can be improved prior
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to a pandemic. We are also exploring whether or not developments in routine data management, such as
electronic emergency department records, can be harnessed to improve case identification and
data completeness.
This is particularly important with regard to minimising the rate of missing outcome data. Some 26 of
155 patients (17%) did not have 30-day follow-up recorded and hence we were unable to verify whether
or not they had an adverse outcome. It was not clear why this rate was so high, as 30-day follow-ups
involved only record review. It may have reflected a low priority for research nurses, as the pilot might have
lacked salience during a quiet influenza season, and recruitment to the pilot was not subject to any target
or sanction (unlike studies involving patient consent). We are involved in ongoing efforts to ensure that
research nurse support will be appropriate and sufficiently motivated in the event of a pandemic. For
example, we have produced online screencast demonstrations of how to collect and manage the data.
It is also worth noting that data linkage methods that were not available for the pilot will be available in
the pandemic study. The CAG approved the proposed use of the NHS number to link our data to ONS and
ICNARC data in the event of a pandemic but was not able to approve this for the pilot study. This linkage
can be used in a pandemic to identify those who have died or been admitted to critical care. If the risks
of failed linkage or adverse events occurring outside critical care are accepted, and patients with no ONS
or ICNARC event are assumed to have had no adverse event, then linkage methods could provide close
to 100% follow-up. Developments in electronic data recording and linkage could facilitate efficient
30-day follow-up within hospitals and further reduce the risk of missing data. For these reasons we have
decided not to revise the sample size calculation for the pandemic study to take missing outcome data
into account.
In summary, the pilot has achieved the objectives of developing acceptable data collection methods, but
only limited conclusions about case identification and data completeness to be drawn from a pilot in
seasonal influenza and applied to a pandemic. On one hand, a pandemic is likely to be associated with
overstretched resources that may further limit our ability to minimise missing data. On the other hand,
PAINTED may achieve a higher profile and priority in a pandemic than is possible for a pilot phase that was
undertaken during a relatively quiet influenza season.
Some changes to the protocol were required as a result of the pilot. As outlined above, we were unable to
obtain Section 251 approval for the use of personal data and therefore undertook the pilot using only
anonymised data. For the pandemic study, we obtained approval to use the NHS number to allow linkage
to ONS and ICNARC data. This will provide a simple way of checking for missed adverse outcomes but will
not allow us to contact GPs for additional follow-up data. The likelihood of additional adverse events being
identified through GP contact is low and, in the event of a pandemic, unlikely to be feasible. We therefore
intend to accept this small risk of patients being misclassified as not having an adverse outcome.
The process of addressing the requirements of the Information Governance Toolkit for CAG approval
created a substantial and unanticipated additional burden. However, by developing the role of the
Information Governance Lead in our institution, and developing an Information Governance Policy that can
be maintained and applied to similar future projects, we have ensured that (hopefully) this issue will be
easier to address in future projects.
The process of obtaining research governance approvals involved, as expected, varying degrees of delay.
The process of obtaining approvals in hospitals in the devolved nations and, in particular, addressing
different approaches to the use of confidential data, involved substantial additional work. We believe
that for the PAINTED study this additional work is, on balance, worthwhile, given the importance of
achieving coverage across the whole of the UK. Other projects that do not need to achieve such wide
geographical coverage may regard the additional bureaucratic obstacles associated with undertaking a
study across different regulatory regimes as a sufficient obstacle to warrant limiting to one area.
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Maintenance of the project and activation in the event of
a pandemic
The pilot phase is now completed and the project has been put on hold until a pandemic occurs.
However, the protocol will need to be regularly reviewed and updated to ensure that it remains valid and
relevant to the needs of the NHS. The following specific issues need to be regularly reviewed:
1. evidence for triage methods and predictors of adverse outcome in influenza
2. case identification, in particular the diagnostic criteria for suspected influenza and potential use of rapid
diagnostic testing methods
3. national and international pandemic planning guidance
4. the ethical and regulatory framework for undertaking research, particularly in relation to using data
without consent
5. data collection and management in emergency departments, particularly the use of electronic
patient records.
Responsibility for PAINTED has now been passed to the Sheffield CTRU. Members of the project team
remain engaged in the project but, with the exception of the Chief Investigator, all project roles and
contact details are now role specific rather than person specific. This means that the project remains
potentially active as long as the Chief Investigator is in post.
Detailed maintenance and activation plans have been drawn up to guide maintenance of the project until
a pandemic and activation in the event of a pandemic. The maintenance plan involves an annual review of
the project with the following key elements:
1. Update the literature review of predictors of adverse outcome in suspected influenza. This has been
done for the first annual review in 2014 and is included in Appendix 1 of this report.
2. Review of international and national pandemic planning guidance and expert contact to identify
development in pandemic planning, influenza diagnosis and treatment. The 2014 update has identified
development in point-of-care testing for influenza,61 which may have implications for case identification
in the future but has not yet been adopted into national guidance.
3. Contact with participating hospitals to ensure they remain willing and able to support the pandemic
phase, and that regulatory approvals remain in place.
4. Review of expressions of interest from potential participating hospitals and, if appropriate, replacement
of existing hospitals with new hospitals.
5. Contact with all members of the project team and steering committee to ensure that they remain
willing to undertake their roles in the event of a pandemic. If appropriate, replacement of any members
of the project team or steering committee who are unable to continue to fulfil their role.
6. Updating the protocol and review by the project team.
7. Informing the REC and CAG of any amendments to the protocol and, if appropriate, seeking approval
for any substantial amendments.
8. Review of the maintenance and activation plans.
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Recommendations for further research
The obvious recommendation for further research as a result of this pilot study is that the main study
should be undertaken if and when a pandemic occurs. Regulatory approvals are in place, data collection
methods have been developed and tested, and a process is in place to ensure that the protocol is regularly
updated and readiness to undertake the research is maintained.
The pilot study has identified potential problems with missing data and these could be explored through
further pilot work. However, given the difficulty of generalising conclusions from pilot work undertaken in
a seasonal influenza to a full study undertaken in a pandemic, there is probably little value in simply
repeating attempts to pilot the standardised assessment form in future influenza seasons. Instead, further
research should involve using developments in routine data management and other technologies to
develop the proposed pandemic research methods. For example, the increasing use of electronic data
capture in emergency departments may provide the opportunity to develop an electronic CAF, thus
reducing the risk of missing data by making data collection more efficient and integrated into routine care.
Developments in linkage between administrative data sources could be used to simplify the collection of
follow-up data and reduce the risk of missing outcome data. The development of rapid influenza testing
could be integrated into hospital information systems to ensure that all cases receiving testing were
identified and included in a pandemic study.
Conclusions
An observational cohort study to identify the most accurate triage method for predicting severe illness
in emergency department attendees with suspected pandemic influenza is set up and ready to activate in
a pandemic. Clinician views of the standardised CAF are generally positive. We were able to collect usable
data using the standardised CAF, although problems of missing data were identified and the paucity of
seasonal influenza cases limited our ability to fully test how case identification and data collection will
proceed in pandemic.
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Appendix 1 Studies evaluating clinical predictors
of adverse outcome in pandemic influenza
Author Site Subjects N Outcome Variable Results
Rowan
(ICNARC)10
UK ICU, suspected
H1N1
(NB: Only 562
confirmed)
1725 Death Current/recent
pregnancy
HR 0.13 (95% CI
0.19 to 0.98);
p= 0.048
Severe chronic
organ dysfunction
HR 1.53 (95% Cl
1.16 to 2.02);
p= 0.008
Immunocompromised HR 1.65 (95% Cl
1.16 to 2.33);
p= 0.005
SOFA score
(per point)
HR 1.05 (95% Cl
1.02 to 1.08);
p= 0.001
Capelastegui13 Spain Hospitalised,
> 18 years
618 Severe
complication
(death, IPPV,
septic shock,
ARDS,
‘resuscitation
manoeuvres’
Age OR 2.6 (95% Cl 1.4
to 5) 46–65 years;
2.8 (95% Cl 1.3
to 6) >65 years
Male OR 2.2
(95% Cl 1.3 to 3.8)
Smoker OR 2.1 (95% Cl
1.1 to 3.9) yes;
2.2 (95% Cl 1.1
to 4.4) ex
No. of comorbidities OR 2.9 (95% Cl
1.4 to 5.8) > 2
(ref. 0)
Multilobar/bilateral OR 2.5 (95% Cl
1 to 5.9)
Pneumonia OR 1.8 (95% Cl 1
to 3)
Confusion OR 3.9 (95% Cl
1.8 to 8.5)
Fever OR 0.4 (95% Cl
0.2 to 0.8)
Dyspnoea OR 4.7 (95% Cl
2 to 11)
Score: 1 point for
age > 45 years,
male, > 2
comorbidities,
pneumonia; 2 points
for confusion,
dyspnoea
AUROC 0.74
(95% Cl 0.68
to 0.8)
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Author Site Subjects N Outcome Variable Results
Miller14 Utah ICU admission,
age > 15 years,
PCR confirmation
of H1N1
47 ICU
admission
Hispanic 23% vs. 13%
population;
p= 0.01
Pacific/Hawaiian 26% vs. 1%
population;
p< 0.001
BMI 30–39 kg/m2 38% vs. 19%
population;
p< 0.001
BMI > 39 kg/m2 36% vs. 3%
population;
p< 0.001
Nguyen-Van-Tam
(FLU-CIN)15
UK Hospitalised,
confirmed H1N1
631 Death/
ICU/HDU
Chronic lung disease
(not asthma/COPD)
OR 3.41 (95% CI
1.33 to 8.71);
p= 0.010
Obesity OR 6.96 (95% Cl
1.46 to 27.28);
p= 0.008
Altered consciousness OR 1.11 (95% Cl
1.04 to 1.17);
p= 0.001
CXR pneumonia OR 5.28 (95% Cl
2.95 to 9.47);
p= 0.001
CRP > 100mg/dl OR 4.41 (95% Cl
2.14 to 9.1);
p= 0.001
SaO2 < 94% on air OR 3.6 (95% Cl
2.17 to 6.27);
p= 0.001
ANZIC16 Australia/
New Zealand
ICU-confirmed
H1N1
722 ICU
admission
Pregnancy 9.1% vs. 1%
population
BMI > 35 kg/m2 28.6% vs. 5.3%
population
Chronic
pulmonary disease
32.7% vs. 13%
population
Maori/Pacific
islander
25% vs. 13.6%
population
Harris17 Australia H1N1 confirmed 181 Hospital
admission
Aboriginal/Torres
Strait
37.7% vs. 60.3%;
p= 0.004
Pregnant 29% vs. 8.1%;
p= 0.013
DM 24.6% vs. 4.2%;
p< 0.001
Renal disease 18% vs. 3.3%;
p= 0.001
Cardiac disease 26.2% vs. 8.3%;
p= 0.001
Obese 28.3% vs. 10%;
p= 0.002
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Author Site Subjects N Outcome Variable Results
Santa-Olalla18 Spain Inpatients, H1N1 3025 ICU/death Asthma 14.5% vs. 22.7%;
p< 0.001
COPD 11.5% vs. 16.9%;
p< 0.001
BMI > 40 kg/m2 19.3% vs. 11.1%;
p< 0.001
Diabetes 13.8% vs. 9.4%;
p< 0.001
Other metabolic
disease
11.5% vs. 8.8%;
p= 0.001
Cardiovascular
disease
16.1% vs. 9.6%;
p< 0.001
Chronic hepatic
disease
9% vs. 6.1%;
p= 0.025
Seizures 6.5% vs. 3.4%;
p= 0.001
Chronic renal
insufficiency
7.3% vs. 4.1%;
p= 0.003
Cui19 China Inpatient, H1N1 68 Death BMI > 27 kg/m2 8/10 death vs. 14/
58 alive; p= 0.001
Zimmerman20 Israel Adults, CDC
definition, PCR
confirmation
191 ICU
admission
SaO2 Median 92% vs.
97%; p= 0.006
Examination lung
findings
71% vs. 31%;
p= 0.002
CRP Median 123 vs.
40; p< 0.001
Martin-Loeches21 Spain Adults, ICU
admission for
respiratory
failure, no
pre-existing CRF,
microbiological
confirmation
661 Acute kidney
injury
Diabetes 16.2% vs. 9.2%;
p= 0.04
SOFA score Mean 8.7 vs. 4.8;
p< 0.001
MODS 92.4% vs. 54.7%;
p< 0.001
WCC 8.3 vs. 6.8;
p< 0.001
CK 290 vs. 170;
p< 0.001
CRP 28 vs. 20;
p< 0.001
Echevarría-Zuno22 Mexico Confirmed H1N1 6945 Death Chronic disease OR 6.1 (95% Cl
2.37 to 15.99)
Tachypnoea OR 4.26 (95% Cl
2.14 to 8.47)
Cyanosis OR 3.46 (95% Cl
1.63 to 7.31)
Time of onset to
admission (days)
OR 1.19 (95% Cl
1.11 to 1.28)
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Author Site Subjects N Outcome Variable Results
Louie23 USA Age < 18 years,
hospitalised,
H1N1
345 Death/ICU Hispanic (vs. white) OR 0.4 (95% Cl
0.2 to 0.8)
Pulmonary disease OR 1.6 (95% Cl
1.0 to 2.6)
Cardiac disease OR 4.3 (95% Cl
1.9 to 9.5)
Neurological disease OR 2.8 (95% Cl
1.6 to 5.0)
Gastrointestinal
disorder
OR 2.4 (95% Cl
1.3 to 4.5)
Acute altered
mental status
2% vs. 15%;
p< 0.001
Stein24 Israel Age < 18 years,
hospitalised,
H1N1
478 ICU
admission
Neurological disease 19% vs. 7.6%;
p= 0.02
Cardiovascular
disease
14.3% vs. 5.7%;
p= 0.03
Metabolic disease 9.5% vs. 1.6%;
p= 0.01
Tachypnoea 61.9% vs. 34.9%;
p= 0.001
Hypoxia 57.1% vs. 21.8%;
p< 0.001
CXR effusion 9.5% vs. 2.1%;
p= 0.005
CXR diffuse infiltrate 33.3% vs. 8.1%;
p< 0.001
Vasoo25 USA ED presentations,
H1N1
83 Admission
ICU
History of prematurity 18.8% vs. 0;
p= 0.002
Haemoglobinopathy 12.5% vs. 0;
p= 0.02
Chronic
neurological disease
OR 6.9 (95% Cl
1.3 to 35.5)
Malignancy 9.4% vs. 0;
p= 0.054
Tachypnoea OR 4.7 (95% Cl
1.7 to 13)
SaO2 < 92% 31.3% vs. 0;
p< 0.0001
Acute renal failure 15.6% vs. 0;
p= 0.007
CXR infiltrate 37.9% vs. 0;
p= 0.001
Chronic
pulmonary disease
OR 4.5 (95% Cl
1.4 to 14.0)
History of prematurity OR 30 (95% Cl
3.2 to 281.8)
Chronic
neurological disease
OR 4.1 (95% Cl
1 to 17.7)
Tachypnoea OR 5.4 (95% Cl
1.7 to 17.5)
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Author Site Subjects N Outcome Variable Results
SaO2 < 92% OR 84.9 (95% Cl
9.3 to 772)
Acute renal failure OR 22.0 (95%Cl
2.3 to 214.2)
CXR infiltrate 68.9% vs. 37.9
(inpatients);
p< 0.0001
Bagdure26 USA Paediatric
admission, H1N1
307 PICU Neurological disorder 38% vs. 19%;
p= 0.002
Immunocompromised 3% vs. 9%; p=0.08
Seizures (acute) 15% vs. 3%;
p< 0.001
Mental status
change
20% vs. 2%;
p< 0.001
Hypoxia 76% vs. 58%;
p= 0.007
Decreased breath
sounds
48% vs. 30%;
p= 0.006
WCC < 4× 109/l 13% vs. 26%;
p= 0.04
CRP > 1mg/dl 82% vs. 57%;
p= 0.03
pH< 7.35 75% vs. 27%;
p= 0.002
Fajardo-Dolci27 Mexico First 100 H1N1
confirmed deaths
100 Death Cardiovascular
disease
20.9% vs. 4.1%
population
Metabolic syndrome 39.5% vs. 14.5%
population
DM 19.8% vs. 7%
population
Respiratory disease 8.1% vs. 0.4%
population
Hypertension 19.8% vs. 15.4%
population
Lee28 Hong Kong Adults, seasonal
flu A/B
754 Death Oseltamivir, Tamiflu®
(Roche)
HR 0.27 (95% Cl
0.13 to 0.55);
p< 0.001
Male HR 3.92 (95% Cl
1.8 to 8.57);
p= 0.001
Major comorbidity HR 2.27 (95% Cl
1.02 to 5.09);
p= 0.045
Libster29 Argentina Age < 18 years,
confirmed H1N1
by PCR
251 ICU
admission
Asthma OR 4.92 (95% Cl
1.38 to 17.33);
p= 0.002
Chien30 Korea H1N1 pneumonia 96 IPPV/NIV Pregnancy 2% vs. 9%; p=0.05
Chronic renal
insufficiency
14% vs. 1%;
p= 0.04
SOFA 4 vs. 1; p= 0.000
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Author Site Subjects N Outcome Variable Results
Jain31 USA Confirmed H1N1 272 ICU/death Age (years) Median 19 vs. 29
Neurocognitive
disease
5% vs. 13%
Neuromuscular
disease
5% vs. 13%
CXR pneumonia 28% vs. 73%
Antivirals < 48 hours 45% vs. 23%
Tuite32 Canada Confirmed H1N1 3152 Death Age > 50 years OR 28.6 (95% Cl
7.3 to 111.2)
Campbell33 Canada Hospital
admission, H1N1
1479 Death/ICU Heart disease RR 2.1 (95% Cl
1.6 to 2.7)
DM RR 2.2 (95% Cl
1.7 to 2.7)
Immunosuppression RR 1.5 (95% Cl
1.1 to 2.0)
Aviram34 Israel ED H1N1, CXR in
24 hours
97 ICU/death Bilateral opacities 60% vs. 15%;
p= 0.049
Multizonal opacities 60% vs. 6%;
p= 0.01
Bassetti35 Italy Inpatients,
confirmed H1N1
81 ICU/death Neurocognitive
disease
33.3% vs. 7%;
p= 0.02
COPD/asthma 19.7% vs. 50%;
p= 0.03
Pneumonia
on admission
100% vs. 44%;
p= 0.0008
Xi36 China Adult
inpatients, H1N1
155 Inpatient
death
Hypertension 37% vs. 19.5%;
p= 0.048
Dyspnoea at
presentation
77.8% vs. 47.7%;
p= 0.004
Pebody37 UK UK national
statistics
(estimated case
fatality rate)
440 deaths Death Chronic renal
disease
RR 36.3 (95% Cl
20.9 to 63.2)
Heart disease RR 15.2 (95% Cl
9.6 to 24.1)
Respiratory disease RR 11.3 (95% Cl
7.9 to 16.1)
Liver disease RR 63.3 (95% Cl
38.6 to 103.7)
DM RR 9.2 (95% Cl
5.6 to 14.9)
Immunosuppression RR 52.8 (95% Cl
36.3 to 76.6)
Stroke/TIA RR 7.5 (95% Cl
2.3 to 23.7)
Chronic
neurological disease
RR 115.3 (95% Cl
84.3 to 157.6)
Wilking38 Germany National statistics 226,075 Death Age 15–34 years (ref.
35–60 years)
OR 0.18 (95% Cl
0.13 to 0.26)
Age > 60 years OR 5.4 (95% Cl
3.86 to 7.56)
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Martin-Loeches39 Spain ICU admission,
PCR-confirmed
H1N1 (also
assessed 2010–11
post pandemic)
648 Death SOFA Mean 4.9 vs.
8.4; p< 0.001
APACHE Mean 12.53 vs.
19.69; p< 0.001
Age (years) Mean 43.7 vs.
48.4; p< 0.001
Comorbidity 69.6% vs. 79.4%;
p= 0.02
Heart failure 6% vs.11%; p=0.03
Chronic renal
disease
4% vs. 10%;
p= 0.003
Autoimmune disease 2.6% vs. 5.7%;
p= 0.06
Haematological
disease
3.7% vs. 14.9%;
p< 0.001
Respiratory
coinfection
14.6% vs. 23.4%;
p= 0.01
Pereira40 Multiple
(ESICM)
ICU admission 265 Death SAPS III Mean 51 vs. 60;
p< 0.001
APACHE II Mean 25 vs. 20;
p< 0.001
Delgado-
Rodriguez41
Spain Hospitalised 813 Death/ICU Age 46–65 years
(ref. < 19 years)
OR 2.21 (95% Cl
1.09 to 4.71)
Age > 65 years
(ref. < 19 years)
OR 2.44 (95% Cl
1.03 to 5.83)
Ex-smoker (NB:
Current smoker
not significant)
OR 1.97 (95% Cl
1.07 to 3.52)
COPD OR 2.02 (95% Cl
1 to 3.87)
DM OR 2.25 (95% Cl
1.21 to 4.02)
Corticosteroids OR 3.05 (95% Cl
1.14 to 7.35)
H2 blockers OR 2.08 (95% Cl
1.05 to 6.66)
Two to three
comorbidities (ref. 0)
OR 2.21 (95% Cl
1.09 to 4.6)
More than three
comorbidities (ref. 0)
OR 2.98 (95% Cl
1.47 to 6.24)
Bramley42 USA ICU admission 108 adults+
46 children
Death Illness to admission
< 2 days
10/37 deaths vs.
51/115; p= 0.06
Asthma 4/11 death vs.
33/117; p= 0.05
CXR pneumonia 32/35 death vs.
69/107; p< 0.001
Treatment < 2 days 2/28 death vs.
34/97; p< 0.01
Sepsis syndrome 21/30 death vs.
15/100; p< 0.01
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Chen43 Taiwan Paediatric
admission
61 Death/ICU BMI > 25 kg/m2 3/11 vs. 0/37;
p= 0.008
SOB 8/14 vs. 8/47;
p= 0.008
CRP > 3mg/dl 6/12 vs. 5/46;
p= 0.008
Secondary bacterial
infection
4/14 vs. 2/47;
p= 0.03
Infiltration on CXR 6/14 vs. 33/42;
p= 0.03
Pleural effusion on
CXR
3/14 vs. 0/42;
p= 0.02
Chen44 Taiwan ED presentations
(NB: 2007–9,
all flu)
146 Hospital
admission
Underlying illness 89% admission
vs. 69%
SOB 13% admission
vs. 6%
Headache 0% admission
vs. 5%
General ache 2% admission
vs. 8%
CXR positive finding 29% admission
vs. 15%
WCC High 9%
admission vs. 6%,
low 25 vs. 19
Neutrophil High 25%
admission vs. 12%,
low 11 vs. 9
Hb Low 29% admission
vs. 20%
Kok45 Australia ICU admission 173 Death
(hospital)
Obesity 6% in obese vs.
20% non-obese
NB: Non-significant
when corrected for
severity of illness
Estella46 Spain Hospital
admission with
viral pneumonia
24 ICU
admission
SaO2 96.6± 2 ward vs.
87.7± 5 ICU
Garnacho-
Montero47
Spain ICU admission,
H1N1
1120 Death Age > 65 years 32% mortality
vs. 22%
Garnacho-
Montero47
Spain ICU admission,
H1N1,
age > 65 years
(subgroup of
above)
129 Death Haematological
disease
OR 5.1 (95% Cl
1.7 to 14.7)
Immunosuppression OR 3.7 (95% Cl
1.5 to 8.7)
> 48 hours before
oseltamivir
OR 2.7 (95% Cl
0.9 to 7.6)
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Esterman48 Australia Admission
< 6 months
28 Admission Smoker in
household
36% vs. 20%
population
NICU/SCBU 25% vs. 14.4%
population
Preterm birth 14% vs. 8.2%
population
Median household
size
5 vs. 2.5 population
Dalziel49 International
(PERN)
Children,
admission
265+ 265
age matched
Severe
outcome
Asthma OR 2.7 (95% Cl
1.7 to 4.2)
Chronic lung disease OR 9.8 (95% Cl
4.2 to 22.8)
Heart disease OR 6.0 (95% Cl
2.3 to 15.5)
Renal disease OR 8.0 (95% Cl
1.0 to 64.0)
Cerebral palsy OR 34.5 (95% Cl
8.5 to 141)
Preterm birth OR 4.1 (95% Cl
2.0 to 8.5)
Dyspnoea OR 9.9 (95% Cl
5.7 to 17.1)
Increase/purulent
sputum
OR 11.0 (95% Cl
3.4 to 35.9)
Seizures (acute) OR 5.6 (95% Cl
2.2 to 14.5)
Irritable/drowsy OR 2.9 (95% Cl
1.7 to 5.1)
Wheeze (complaint) OR 7.0 (95% Cl
3.5 to 14.10)
Respiratory rate OR 0.15 (95% Cl
0.046 to 0.26)
Heart rate OR –0.19 (95% Cl
–0.3 to –0.086)
SaO2 < 93%/
supplemental O2
OR 39.7 (95% Cl
12.6 to 125)
Chest retraction OR 18.5 (95% Cl
9 to 38)
Accessory muscle
use
OR 25.2 (95% Cl
10.7 to 59.7)
Crepitations OR 7.8 (95% Cl
4.1 to 14.8)
Wheeze on
examination
OR 8.1 (95% Cl
4.6 to 14.4)
Prolonged CRT OR 16.7 (95% Cl
5.2 to 53.4)
Altered mental
status
OR 76.3 (95% Cl
10.3 to 564)
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Author Site Subjects N Outcome Variable Results
Signs of dehydration OR 12.3 (95% Cl
4.5 to 33.6)
Abnormal CXR OR 6.2 (95% Cl
3.1 to 12.5)
Lopez-Delgado50 Spain ICU with
respiratory failure
from H1N1
60 Hospital
mortality
BMI > 30 kg/m2 37% survivor vs.
0%; p= 0.021
Dyslipidaemia 18% survivor vs.
8%; p= 0.049
Creatinine 108.4± 74 survivor
vs. 186.4± 220;
p= 0.043
Hb 13± 2 survivor vs.
11.4± 3.2;
p= 0.033
Platelets 214 ± 101 survivor
vs. 113± 82;
p= 0.002
pH 7.4± 0.7 survivor
vs. 7.28± 0.15;
p< 0.001
PCO2 (mmHg) 41± 21 survivor vs.
58± 24; p= 0.04
Bacterial coinfection 10.4% survivor vs.
41.6%; p= 0.022
Greenbaum51 USA Hospitalised,
18–65 years, with
lab-confirmed flu
(not all pandemic)
9092 Mortality or
ICU admission
Heavy alcohol use RR 1.34 (95% Cl
1.04 to 1.74)
Chronic lung disease RR 1.35 (95% Cl
1.23 to 1.48)
Asthma RR 0.85 (95% Cl
0.77 to 0.93)
Cardiovascular
disease
RR 1.12 (95% Cl
1.02 to 1.24)
Chronic metabolic
disease
RR 1.29 (95% Cl
1.19 to 1.4)
Greenbaum51 USA Hospitalised,
> 65 years, with
lab-confirmed flu
(not all pandemic)
6584 Mortality or
ICU admission
Heavy alcohol use RR 2.47 (95% Cl
1.69 to 3.6)
Chronic lung disease RR 1.51 (95% Cl
1.36 to 1.68)
Cardiovascular
disease
RR 1.41 (95% CI
1.26 to 1.57)
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Delgado-
Rodriguez52
Spain Hospitalised with
lab-confirmed flu
1520 Mortality or
ICU admission
Respiratory failure OR 2.14 (95% Cl
1.12 to 4.08)
Cardiovascular
disease
OR 3.10 (95% Cl
1.89 to 5.09)
Cancer OR 2.61 (95% Cl
1.61 to 4.24)
Systemic steroids
pre-admission
OR 4.69 (95% Cl
2.46 to 8.95)
Pneumonia at
admission
OR 1.98
(95% Cl 1.33
to 9.5)
No. organ
malfunction at
admission
(continuous)
OR 3.31 (95% Cl
2.62 to 4.2)
Alcohol > 80 g/day OR 1.99
(95% Cl 1.09
to 3.64)
Borse53 India Adult ICU
admission with
lab-confirmed
H1N1
100 Hospital
mortality
No significant clinical
or radiological
predictors
Mortensen54 California Hospitalised/died
with influenza A
and asthma
170 ICU
admission/
death
Renal disease OR 3.87
(95% Cl 1.08
to 13.87)
Infiltrates on CXR OR 9.71
(95% Cl 3.93
to 23.99)
Semple55 UK Hospitalised
(FLU-CIN),
> 16 years
1040 HDU/ICU/
death
Severe respiratory
distress
OR 2.27 (95% Cl
1.63 to 3.16)
Increased respiratory
rate
OR 2.37 (95% Cl
1.69 to 3.31)
SaO2 < 93% OR 6.42 (95% Cl
4.49 to 9.18)
Respiratory
exhaustion
OR 6.13 (95% Cl
2.64 to 14.2)
Severe dehydration/
shock
OR 2.89 (95% Cl
2.01 to 4.16)
Altered consciousness OR 4.99 (95% Cl
2.82 to 8.81)
Other clinical
concern
OR 2.19 (95% Cl
1.39 to 4.36)
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Author Site Subjects N Outcome Variable Results
Hospitalised,
(FLU-CIN)
< 16 years
480 Severe respiratory
distress
OR 3.16 (95% Cl
1.91 to 5.22)
SaO2 < 93% OR 4.95 (95% Cl
2.97 to 8.25)
Severe dehydration/
shock
OR 11 (95% Cl
1.98 to 61.1)
Altered consciousness OR 6.44 (95% Cl
3.49 to 11.9)
Other clinical
concern
OR 2.38 (95% Cl
1.16 to 4.9)
Kusznierz56 Argentina Hospitalised,
lab-confirmed
H1N1
242 Death Obesity 4% survivor vs.
40%; p< 0.001
DM 6% survivor vs.
19%; p= 0.002
Heart disease 6% survivor vs.
19%; p= 0.02
Hypertension 16% survivor vs.
38%; p= 0.03
Renal disease 4% survivor vs.
11%; p= 0.04
CXR consolidation 75% survivor vs.
38%; p< 0.001
Secondary bacterial
infection
0.6% survivor vs.
7%; p= 0.002
ARDS 19% survivor vs.
72%; p< 0.001
Sepsis/shock 6% survivor vs.
54%; p< 0.001
Tamiflu® < 48 hours 27% survivor vs.
13%; p= 0.012
Mertz57 Multiple Meta-analysis
(seasonal flu)
75,871 Death Obesity OR 30.10 (95% Cl
1.17 to 773.12)
Cardiovascular
disease
OR 1.97 (95% Cl
1.06 to 3.9)
Immunocompromised OR 3.81 (95% Cl
1.28 to 11.35)
Endocrine disease OR 13.92 (95% Cl
3.71 to 52.13)
ICU
admission
Chronic lung disease OR 4.46 (95% Cl
1.34 to 14.79)
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Meta-analysis
(pandemic flu)
534,911 Death < 4/52 post partum OR 4.43 (95% Cl
1.24 to 15.81)
Obesity OR 2.74 (95% Cl
1.56 to 4.8)
Chronic lung disease OR 1.71 (95% Cl
1.17 to 2.51)
Cardiovascular
disease
OR 2.92 (95% Cl
1.76 to 4.82)
Immunocompromised OR 3.67 (95% Cl
1.78 to 7.58)
Malignancy OR 3.1 (95% Cl
2.35 to 4.1)
Neuromuscular
disease
OR 2.68 (95% Cl
1.91 to 3.75)
Anaemia/
haemoglobinopathy
OR 2.28 (95% Cl
1.35 to 3.84)
DM OR 2.21 (95% Cl
1.37 to 3.57)
Liver disease OR 2 (95% Cl
1.32 to 3.04)
Metabolic disease OR 1.83 (95% Cl
1.19 to 2.79)
Renal disease OR 3.11 (95% Cl
1.54 to 6.28)
ICU
admission
Obesity OR 1.81 (95% Cl
1.48 to 2.22)
Chronic lung disease OR 1.48 (95% Cl
1.19 to 1.83)
Cardiovascular
disease
OR 1.7 (95% Cl
1.39 to 2.08)
Neuromuscular
disease
OR 2.63 (95% Cl
1.83 to 3.79)
DM OR 1.6 (95% Cl
1.32 to 1.94)
Liver disease OR 2.65 (95% Cl
1.44 to 4.88)
APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; AUROC, area under
the receiver operator characteristic curve; BMI, body mass index; CDC, Centers for Disease Control; CK, creatine kinase;
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CRT, capillary refill time; DM, diabetes mellitus;
ED, Emergency department; ESICM, European Society of Intensive Care Medicine; FLU-CIN, Influenza Clinical Information
Network; Hb, haemoglobin; HDU, high dependency unit; HR, hazard ratio; ICU, intensive care unit; IPPV, intermittent
positive-pressure ventilation; MODS, multiple organ dysfunction score; NICU, Neonatal Intensive Care Unit;
NIV, non-invasive ventilation; OR, odds ratio; PCR, polymerase chain reaction; PERN, Pediatric Emergency Research
Networks; SaO2, arterial oxygen saturation; SAPS III, ICU scoring system; SCBU, special care baby unit; SOB, shortness of
breath; SOFA, Sequential Organ Failure Assessment; TIA, transient ischaemic attack.
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Appendix 2 The PAndemic INfluenza Triage
in the Emergency Department study protocol
Research objectives
We aim to identify the most accurate triage method for predicting severe illness among patients attending
the emergency department with suspected pandemic influenza.
Our specific objectives are:
1. to determine the discriminant value of emergency department triage methods for predicting severe
illness in patients presenting with suspected pandemic influenza
2. to determine the discriminant value of presenting clinical characteristics and routine tests for identifying
severe illness
3. to determine the independent predictive value of presenting clinical characteristics and routine tests for
severe illness
4. to develop two new triage methods based upon (a) presenting clinical characteristics alone and
(b) presenting clinical characteristics, electrocardiogram (ECG), chest X-ray and routine blood test results.
Existing research
Prior to the 2009 H1N1 pandemic, the United Kingdom (UK) influenza pandemic contingency plan
predicted around 750,000 excess emergency department attendances and 82,500 excess hospitalisations
during a pandemic.1 A recent consultation document suggested that a pandemic could result in 50%
of the population having some symptoms, of whom 30% would seek primary care and 1–4% would
need hospital admission.2 The Pandemic Influenza Advisory Committee Subgroup on Modelling have
estimated a likely clinical attack rate of 3–35% (worst case scenario 50%), with 10–25% of these to have
complications and a peak demand in the worst case scenario of 13% of the population being ill.3
Pandemic planning needs to encompass a wide range of potential scenarios, but even projections at
the less severe end of the spectrum could cause substantial problems of overcrowding at emergency
departments that are already often working close to capacity. Methods of triage for patients presenting
to the emergency department with suspected pandemic influenza are therefore required and need to be
fair, robust and reproducible.4
The term triage is often used to describe a brief initial assessment in the emergency department to
determine patient order of priority in the queue to be seen. In this proposal we use the term triage more
broadly to include the full process of emergency department assessment, potentially including
investigations such as blood tests and X-rays, and apply it to decision-making regarding whether the
patient should be admitted and whether they should be referred for high dependency or intensive care.
Emergency department triage methods need to accurately predict the individual patient’s risk of death
or severe illness. The predicted risk can then guide decision-making. Patients with a low risk may be
discharged home, those with a high risk admitted to hospital, and those with a very high risk referred for
high dependency or intensive care. The level of risk used to trigger these decisions need not necessarily be
fixed or determined in advance. Indeed, it is likely that decision-making thresholds could change during
the course of a pandemic as the balance between resource availability and demand changes. Triage
methods that use a risk prediction score to determine the need for hospital care may therefore be more
useful than a triage rule that classifies patients into admission and discharge categories.
DOI: 10.3310/hta19030 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 3
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Health Protection Agency (HPA) guidance prior to the 2009 pandemic, supported by the British
Thoracic Society and British Infection Society, recommended the use of the CURB-65 pneumonia score5
for patients with suspected influenza-related pneumonia. This score uses five variables (confusion,
urea level, respiratory rate, blood pressure and age) to generate a score between zero and five.
Subsequent Department of Health guidelines on surge capacity in a pandemic also considered use of a
physiological-social score [Pandemic Modified Early Warning Score (PMEWS)].6 This score uses physiological
variables, age, social factors, chronic disease and performance status to generate a score between zero
and seven. National guidance specific to the 2009 H1N1 pandemic included a swine flu hospital pathway
for emergency department management with seven criteria, any one of which predicts increased risk and
the need for hospital assessment.7
We used the autumn/winter phase of the 2009 H1N1 pandemic in Sheffield and Manchester to evaluate
the discriminant value of three potential systems for triage of pandemic influenza patients in the
emergency department: CURB-65, PMEWS and the swine flu hospital pathway.8,9 However, the pandemic
in these areas was less severe than predicted and only five patients of the cohort of 481 met our
predefined criteria for critical illness. Within this cohort the discriminant value (c-statistic) of the three
systems for predicting critical illness was moderate [CURB-65 0.78, 95% confidence interval (CI) 0.58 to
0.99, PMEWS 0.77 (0.55 to 0.99) and the swine flu hospital pathway 0.70 (0.45 to 0.96)]. Their
performance in predicting hospital admission was worse: CURB-65 0.65 (95% CI 0.54 to 0.76), PMEWS
0.76 (0.66 to 0.86) and the swine flu hospital pathway 0.62 (0.51 to 0.72). These findings suggested that
clinicians were not using the recommended triage methods when deciding whether to admit or discharge
patients, and raised concerns about the accuracy of these methods for predicting adverse outcome.
Other research during the pandemic cast doubt on the utility of existing triage systems. The SwiFT study of
patients admitted to critical care with H1N1 found 68% scored 0 or 1 using CURB-65 (i.e. recommended
for hospital discharge).10 This is supported in evidence from a Canadian seasonal flu cohort, where no
triage system performed well in predicting intensive care admission (c-statistics PMEWS 0.63 (0.57–0.69),
CURB-65 0.58 (0.52–0.64).11 The best discriminator in this cohort was SMART-COP, a system specifically
developed to predict intensive care admission in community-acquired pneumonia12 which achieved a
c-statistic of 0.73 (0.67–0.79) but has not to our knowledge been examined in a pandemic cohort.
The SwiFT study10 also developed a new score based on systolic blood pressure, temperature, heart rate,
respiratory rate, neurological status and inspired oxygen concentration to predict adverse outcome.
The SMART-COP and SwiFT scores therefore offer alternative triage methods that require validation in a
pandemic. We are not aware of any other new scores to emerge since the 2009 pandemic.
In addition to our study and SwiFT, a number of cohort studies were undertaken during the 2009 H1N1
pandemic to identify risk factors for poor outcome in various groups. We have systematically reviewed
these studies and present the main findings in the appendix of this project description. The predominant
predictors of adverse outcome were chronic comorbidities and obesity13–18 with conflicting evidence
regarding the risk of pregnancy.10,15 Acute physiological disturbances, particularly hypoxia, were also found
to have prognostic value.10,14,19–25
The existing research therefore suggests that, although there are a number of patient characteristics and
clinical measures that can predict adverse outcome, the available data do not support the use of any
specific triage methods in suspected pandemic influenza.
Research methods
We plan to undertake a prospective observational cohort study of patients attending the emergency
department with suspected pandemic influenza to evaluate existing triage methods, identify clinical
predictors of adverse outcome and develop new triage methods.
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Predictor variable data collection
Emergency department staff will be provided with a standardised form for assessing patients with
suspected influenza that will double as clinical notes and study data collection form. It will include the
elements of all currently available triage methods, variables identified in previous studies as being
predictors of adverse outcome (see appendix) and any other potential predictors that are routinely
recorded in the emergency department (comorbidities, physiological observations, routine blood tests,
ECG and chest X-ray). We will also record details of any pre-presentation anti-viral medication, antibiotics
and immunisation status.
Planned interventions
We will evaluate triage methods used to determine whether a patient with suspected pandemic influenza
should be admitted to hospital or not, and whether they should be admitted to intensive or high
dependency care. These will include the CURB-65 score, PMEWS, the swine flu hospital pathway,
SMART-COP, the SwiFT score and any new methods developed before the next pandemic. We will also
develop two new triage methods based upon (a) presenting clinical characteristics alone and (b) presenting
clinical characteristics, ECG, chest X-ray and routine blood test results.
The first score will only use variables available at initial patient assessment, i.e. history and examination,
including simple technologies such as automated blood pressure measurement and pulse oximetry.
This triage method can be used to assess patients for the need for hospital investigation and identify
patients that can be discharged without further assessment. It could potentially be used, with appropriate
validation, to assess patients in the community.
The second triage method will be based upon all available emergency department data, including routine
blood tests, ECG and chest X-ray findings. This triage method can be used for two potential purposes:
(1) identification of patients with a low risk of adverse outcome who can be discharged home after
emergency department assessment; and (2) identification of high-risk patients who are likely to need high
dependency or intensive care.
We will evaluate the ability of each method to predict whether patients die or require respiratory, cardiac
or renal support. We will not evaluate the impact of triage methods upon patient care. Intervention in
the study will therefore only consist of data collection and follow-up. Patient management will continue
according to whatever Department of Health guidance is in place at the time of the pandemic.
We will initially aim to develop triage methods that can be applied to the whole population of patients
presenting to the emergency department. Age dependent variables will be assessed and included in the
triage method in relation to age specific normal ranges. We will then explore whether different triage
methods may be appropriate for different patients, particularly whether a different triage method may be
appropriate for children.
Planned inclusion/exclusion criteria
We will include all adults and children presenting the emergency department of the participating hospitals
with suspected pandemic influenza during the peak of the pandemic. Patients will be eligible for inclusion
if they meet the current clinical diagnostic criteria of (1) fever (pyrexia ≥ 38 °C) or a history of fever and
(2) influenza-like illness (two or more of cough, sore throat, rhinorrhoea, limb or joint pain, headache,
vomiting or diarrhoea) or severe and/or life-threatening illness suggestive of an infectious process; or if
they meet any future clinical diagnostic criteria recommended by the Department of Health. The assessing
clinician will determine eligibility and complete the data collection form if the patient is considered to have
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suspected pandemic influenza. We will not attempt to retrospectively apply the clinical diagnostic criteria
and exclude patients who appear to have been inappropriately included. Patients will only be excluded if
they request exclusion from the study.
Proposed outcome measures
Patients will then be followed up until 30 days after attendance by hospital record review. Patients who die
or require respiratory, cardiovascular or renal support they will be defined as having an adverse outcome.
If they survive to 30 days without requiring respiratory, cardiovascular or renal support they will be defined
as having no adverse outcome. If a severe pandemic leads to hospital resources being overwhelmed we
will categorise patients as having an adverse outcome if they were deemed to have needed respiratory,
cardiovascular or renal support but were denied this due to lack of resources. We will also record whether
they are treated with antiviral agents or antibiotics and the length and location of any hospital stay.
At day 30 the data will be entered into the database.
Respiratory support is defined as any intervention to protect the patient’s airway or assist their ventilation,
including non-invasive ventilation or acute administration of continuous positive airway pressure. It does
not include supplemental oxygen alone or nebulised bronchodilators. Cardiovascular support is defined as
any intervention to maintain organ perfusion, such as inotropic drugs, or invasively monitor cardiovascular
status, such as central venous pressure or pulmonary artery pressure monitoring, or arterial blood pressure
monitoring. It does not include peripheral intravenous canulation and/or fluid administration. Renal support is
defined as any intervention to assist renal function, such as haemoperfusion, haemodialysis or peritoneal
dialysis. It does not include intravenous fluid administration.
Outcome assessment will be based primarily on research nurse review of hospital computer records and
case notes. The hospital computer records will be checked at least 30 days after presentation. If the patient
is alive at 30 days, was discharged home from the emergency department and did not reattend hospital,
they will be recorded as having no adverse outcome. If they died, were admitted to hospital or reattended
hospital within 30 days, their hospital notes will be retrieved and reviewed by the research nurse. If there is
no evidence in the hospital notes of an adverse outcome the patient will be recorded as having no adverse
outcome. We intend to cross check the completeness of the dataset by comparing NHS numbers with the
Intensive Care National Audit and Research Centre (ICNARC) database and the Office for National Statistics
(ONS). The cross-check with ICNARC will be to determine that our dataset has captured all intensive care
usage and associated adverse outcomes. Should there be cases in the ICNARC database that are not
present in the PAINTED database we would endeavour to retrieve the missing clinical data (linking the
cases via the NHS number) to supplement the PAINTED dataset. Capturing missing mortality data will be
undertaken via a search organised by the ONS. Linking of records would again be made using the NHS
number. If outcome still is uncertain (for example, if patient records are not obtainable) this will be
recorded as no adverse outcome.
We have selected an outcome measure that has a relatively clear definition and unequivocally indicates a
case in which hospital admission and high dependency care would be desirable. The disadvantage of this
definition is that it excludes patients who might benefit from other aspects of hospitalisation, such as
oxygen supplementation or intravenous fluids. However, oxygen and intravenous fluids are often
administered to patients with little clinical need for these treatments, administration is often poorly
recorded and administration may be based on the clinical variables being tested in this project rather than
objective clinical need. Including these treatments in our definitions of respiratory or cardiovascular
support would thus carry a substantial risk of over-estimating the prevalence of serious outcome and
of over-estimating the association between predictor variables and outcome.
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We will also not attempt to determine whether deaths were likely to be amenable to treatment and will
thus not explore the issue of whether treatment would be futile. It is possible that a severe pandemic
could result in a need to identify cases where treatment would be futile, but this is beyond the scope,
and possibly incompatible with the aims, of this proposal.
Proposed sample size
The sample size will ultimately depend upon the size and severity of the pandemic. Our pragmatic data
collection methods will ensure that we maximise any opportunity to evaluate emergency department triage
methods in a pandemic.
Our experience in the 2009 pandemic has shown us that pre-pandemic estimates of case hospitalisation
and case fatality rates can be very misleading and that sample size estimates must take into account
considerable uncertainty in these estimates. Nevertheless, we have also shown that informative findings
can be generated even in a pandemic with a very low rate of adverse outcome.
Given that most cases of suspected pandemic influenza (even in a severe pandemic) do not result in an
adverse outcome, the key variable in determining study power is the number of cases with an adverse
outcome. A single cohort including at least 150 cases with adverse outcome would allow us to estimate
the c-statistic of a triage method, clinical variable or test with a standard error of 0.03 (assuming the true
c-statistic was 0.8). The table below shows the standard error resulting from samples with smaller numbers
of adverse outcomes.
N with adverse outcome Standard error (assuming c-statistic was 0.8)
150 0.033
125 0.036
100 0.040
75 0.046
50 0.056
A sample with N= 150 adverse outcome would estimate the sensitivity of a dichotomised rule, variable or
test with a standard error as outlined in the table below, depending on the sensitivity at the threshold
used. Estimates of specificity would obviously be very precise given the anticipated low prevalence of
adverse outcome.
Sensitivity Lower limit of 95% CI
1.00 0.98
0.95 0.90
0.90 0.84
0.85 0.78
0.80 0.73
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The same cohort could be used to identify independent predictors of outcome and develop new triage
methods (objectives 3 and 4). The number of variables that could be tested as independent predictors of
outcome in a multivariable model and for inclusion in a triage method would depend upon the sample
size. Based on the rule of thumb of needing at least 10 events for each independent regression variable
in a logistic regression, a cohort with 150 cases with adverse outcome would allow us to test up to
15 parameters.26
These estimates assume that each triage method and predictor variable will be used and tested on the
whole cohort. However, we plan to explore whether different patients require different triage methods,
particularly whether a different triage method is required for children and adults. Data from the 2009
H1N1 pandemic suggest that around a quarter to a third of adverse outcomes may occur in children.14,33
To increase the probability that we will have at least 50 cases with adverse outcome among children we
will aim to recruit a total of 200 cases with adverse outcome rather than 150.
If we assume that the prevalence of adverse outcome is the same as our 2009 cohort (1%) then we would
need to collect data from 20,000 cases to identify 200 with an adverse outcome. We have therefore used
this estimate in planning, although it is likely to be a overestimate of the total numbers required given the
mild nature of the 2009 pandemic. A more severe pandemic would allow more precise estimates to be
made with no additional costs or would allow us to reduce the total number of cases required to identify
200 with an adverse outcome.
If we are able to develop a new triage method that appears to have superior discriminant value to existing
methods then we would want to validate this method in a new cohort. A sample including 421 cases with
adverse outcome would provide 80% power to compare an area under the ROC curve of 0.85 versus 0.90
at 5% significance, assuming a correlation of 0.6 between scores. We have not included validation of a
new triage method in our objectives because this would require (a) successful development of a new
method and (b) a much larger sample size, with associated costs and assumptions about pandemic
severity. However, if the pandemic is severe (i.e. the prevalence of adverse outcome exceeds 3%, so the
number with adverse outcome exceeds 450) we will split the cohort into two equal cohorts to allow
testing of existing rules and derivation of new rules on one half and validation of new rules, with
comparison to existing rules, on the other.
We plan to collect data across 40 hospitals and have based our sample size calculation on the assumption
of receiving 500 completed forms, including an average of 5 adverse outcomes, per hospital over the
course of the pandemic.
Statistical analysis
In all analyses only age will be treated as a continuous variable (with possible reparameterisation). All other
continuous variables will be categorised on the basis of their use in existing risk scores or previous studies.
This is because most continuous variables used in risk prediction have a non-linear association with adverse
outcome, with increased risk at high and low values.
It is likely that a proportion of data for most predictor variables (especially blood results) will be missing.
The most likely reason is that a measurement would not be made or test performed if it was expected to
be normal. Missing data will therefore be handled in constructing scores and in multivariable analysis by
assuming that all missing values are normal (i.e. score zero in the relevant risk score). A sensitivity analysis
will be performed by imputing missing values and comparing results between the three scenarios of
excluding cases with missing values, treating missing values as normal and using imputed values for
missing values.
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Existing triage methods will be assessed by calculating the area under the ROC curve (c-statistic)
for discriminating between cases with and without an adverse outcome (defined as death or need for
support of respiratory, cardiovascular or renal function) and sensitivity and specificity at key
decision-making thresholds.
The discriminant value of each clinical variable or test for adverse outcome will be assessed by calculating
the c-statistic and, for dichotomous variables, the sensitivity and specificity.
Independent predictors of outcome will be identified by entering all clinical variables with an association
with outcome (p< 0.2) into a multivariate logistic regression model.
New triage methods will be developed by combining the independent predictors of outcome into two
new triage scores: one based on clinical variables measured at initial assessment only and the other based
on all clinical variables (including blood tests and X-rays) measured in the emergency department.
Integer weights will be assigned to each category of predictor variable according to the coefficient derived
from a multivariate model using categorised independent predictors. This will generate a composite clinical
score in which risk of positive outcome increases with the total score.
To determine whether different clinical scores are required for adults and children we will derive separate
scores for adults (age ≥ 16) and children. If any variables are included in one and not in the other we
will compare c-statistics separately in each age group for models with and without the relevant variable.
We will also test whether the weights attached to each variable differ sufficiently to affect prediction.
The outcome may be that models with different predictors and/or different weights are required for adults
and children.
If the pandemic is severe enough to allow the cohort to be split into derivation and validation cohorts with
sufficient numbers of adverse outcome we will compare new triage methods developed during the project
to existing triage methods by calculating c-statistics and sensitivity/specificity at key decision-making
thresholds in the second cohort.
Data management
Data will be collected by the clinical staff caring for the patient using a standardised clinical assessment
form that will double as routine clinical record and research data collection form. Research nurses
employed by each hospital (and funded by the Comprehensive Local Research Network) will identify
patients with suspected influenza for whom the standardised form was completed. Once 30 days have
passed from attendance the research nurse will check the hospital computer system for deaths or hospital
admissions. If death or hospital admission has occurred (estimated 15% of cases) the research nurse will
retrieve hospital notes to record details of any adverse events. Once complete the research nurse will enter
anonymised data into a secure online database provided by the Sheffield Clinical Trials Research Unit
(CTRU). The only patient identifiable information recorded onto the database and viewable by the research
team will be NHS numbers. We intend to use these to cross check the completeness of the dataset by
comparing NHS numbers with the ICNARC database and the ONS. The cross-check with ICNARC will be
to determine that our dataset has captured all intensive care usage and associated adverse outcomes.
Should there be cases in the ICNARC database that are not present in the PAINTED database we would
endeavour to retrieve the missing clinical data (linking the cases via the NHS number) to supplement the
PAINTED dataset. Capturing missing mortality data will be undertaken via a search organised by the ONS.
Linking of records would again be made using the NHS number.
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Piloting the data collection form
We have piloted and developed a standardised clinical assessment form based on the 2009 pandemic.
Staff at participating hospitals have used the form for routine assessment of patients with seasonal
influenza during the winter of 2012–13. We have sought staff feedback to make the form as user-friendly
as possible and to ensure that it serves dual needs of collecting relevant information for routine clinical
records and the data required for our research. We will promote use of the form so that it becomes the
routine clinical record for patients presenting to the participating hospitals with suspected influenza.
Once the form is developed we will create a secure online database to ensure efficient data management.
We will ensure that the software supporting form production and the database is flexible so that the form
can be amended and updated at short notice and with minimum inconvenience to clinical and research
staff. During the pilot phase and at the point of activation of the full study (see below) we will update our
literature review to identify any new triage methods or potentially useful predictors of adverse outcome.
Activation of the full study
The project will be activated if and when an influenza pandemic results in increased emergency
department attendances with suspected influenza. Research staff will promote the use of the standardised
data collection form, collect follow-up data and undertake data entry. We will update our literature
review (as outlined above) and monitor reports from areas where the pandemic develops to identify
any potentially new predictors of adverse outcome that may be unique to the emerging pandemic. If any
potentially new predictors are identified we will cascade information to clinical staff and amend the clinical
assessment form to ensure that they are systematically recorded.
Ethical arrangements
We have sought Research Ethics Committee (REC) approval prior to piloting and in advance of any
pandemic. We have sought approval to activate the project in the event of a pandemic without a further
REC review. Our previous similar project in the 2009 H1N1 pandemic was approved by the REC.
The planned processes for informing patients of the project and managing data are very similar to those
approved in our 2009 project. During the previous 2009 project patient identifiable information was taken
to allow monitoring, data validation and GP contact. The National Information Governance Board (NIGB)
gave section 251 approval to this use of identifiable patient data without consent. However the NIGB was
unable to give approval to the use of patient identifiable information in the pilot phase of this project.
We will therefore not be collecting identifiable details in the pilot phase, but will use the pilot phase to test
whether the study can be undertaken without identifiable data.
We have assessed the potential limitations incurred by inability to use identifiable details we will pursue
approval to use identifiable details during the pandemic phase from the appropriate competent body.
Risks and anticipated benefits for trial participants and society
The study will not alter patient management and will simply collect routinely available data at presentation
and follow-up. No additional diagnostic tests will be performed. The risks to patients involved in the study
are therefore very low and principally relate to data protection and confidentiality.
The standardised clinical assessment form will be used as both routine clinical record and data collection
form to ensure that care is not delayed by unnecessary duplication of data recording. The pilot phase will
be used to ensure that this form is fit for both purposes and acceptable to clinical staff. The research
nurses will keep a record of all patients who withdraw from the project but will not communicate details
to other staff. Only anonymous data will be entered into the database by the clinical staff. Other than the
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research team’s access to NHS numbers no one outside of the hospital will have access to patient
identifiable information.
Patients involved in the study will potentially benefit from the use of the standardised clinical assessment
form. This will ensure that important variables are recorded and communicated between staff providing
care. The standardised form can also be used to remind staff of current guidance for management.
Future patients with suspected pandemic influenza and society in general will benefit from evaluation and
development of accurate triage methods that have the potential to improve clinical decision-making and
ensure that patients receive the right care and health service resources are optimally used.
Informing potential trial participants of possible benefits and known risks
Posters in all participating departments will be prominently displayed advising patients of the project and
providing contact details for further information. Information leaflets will be provided for staff to hand
to patients with suspected pandemic influenza that briefly describe the nature and purpose of the study
and provides contact details for further information.
Obtaining informed consent from participants
We will not seek patient consent to participate on the basis that the study is limited to collection of
routinely available data and any delays in patient assessment would risk compromising patient care.
The information leaflet outlined above will provide a tear-off slip with contact details that patients can use
to inform the hospital or research team if they wish to withdraw from the study. Patients who wish to
withdraw from the study will have their study records deleted. Their decision to withdraw will not be
communicated to clinical staff providing further care and will not influence their subsequent management.
Proposed time period for retention of relevant study documentation
The original data collection form will constitute the clinical notes and be kept in each hospital according to
normal practice. The anonymised database will be maintained by the Clinical Trials Unit until ten years
after the end of the project.
Proposed action to comply with ‘The Medicines for Human Use
(Clinical Trials) Regulations 2004’
Not applicable – this is not a clinical trial.
Research governance
Sheffield Teaching Hospitals NHS Foundation Trust will be the study sponsor and the project will be
managed by the School of Health and Related Research (ScHARR) in the University of Sheffield.
The Hospital Trust and University share a joint research office in Sheffield to facilitate management of
collaborative projects such as this. The Project Management Group (PMG), consisting of the co-applicants
and any appointed research staff, will manage the study. The PMG will meet prior, during and after the
pilot phase. After that meetings will be held annually until a pandemic emerges and the project is
activated. During the pandemic the PMG will meet at least monthly, either in person or by teleconference.
The Sheffield CTRU will manage data entry, data management and provide data ready for analysis by
Professor Campbell.
A Steering Committee will be formed to oversee study progress. This will consist of an independent Chair
and at least three independent members (including a relevant clinician, statistician and public/patient
representative), the Chief Investigator and the Project Manager.
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Project timetable and milestones
June 2012 to September 2012: REC submission, and seeking regulatory approvals from participating
NHS Trusts.
October 2012 to January 2013: Piloting and development of clinical assessment form.
February 2013: Project put on hold until pandemic emerges (T0)
T0: Project activated
T0 to T0+ 3 months: Data collection from 20,000 cases, including 200 with an adverse outcome, across
40 hospitals (see sample size section for details)
T0+ 3 to T0+ 6 months: Analysis and reporting
Expertise
The research team combines experts on emergency management of suspected pandemic influenza
(KC, DW and AB) with expertise in paediatric emergency medicine (IM), critical care (AB) and public health
(AL), and the statistical expertise and research infrastructure of the Sheffield Clinical Trials Unit (SG, MC
and RW).
The team collaborated on a similar previous project during the 2009 H1N1 pandemic (HTA09/84/66).
This project was completed and reported despite difficulties caused by research governance procedures
and the unexpectedly mild course of the pandemic.
Steve Goodacre was Chief Investigator for HTA09/84/66 and is lead applicant for this proposal. He has
undertaken many major national evaluations in emergency care, including development of clinical
prediction methods. His current projects provide the necessary infrastructure to rapidly undertake the
proposed research. Richard Wilson managed the DAVROS study and has developed extensive expertise in
data collection, management and protection in observation studies using routine data sources without
patient consent. Mike Campbell is an experienced medical statistician with expertise in development and
validation of clinical prediction rules. Andrew Lee is a Senior Clinical University Teacher in Public Health
who has a research interest in emergency planning and is currently collaborating with SG, KC and DW on
an NIHR Service Delivery and Organisation project involving scoping the emergency planning literature.
Kirsty Challen and Darren Walter are emergency physicians with research interests in pandemic influenza
and emergency planning, and Andrew Bentley is an accredited critical care and respiratory physician.
They have previously evaluated triage methods for pandemic influenza and are leading experts in this field.
Ian Maconochie is a paediatric emergency physician who has evaluated paediatric early warning scores,
the predictive value of clinical features in sick children and the management of febrile children.
Service users
Enid Hirst has agreed to be the patient/public representative for the project and has reviewed the
proposal. She acted as patient and public representative for our project in the 2009 pandemic and was
an independent member of the study Steering Committee.
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Enid is a founder member of the Sheffield Emergency Care Forum. This is a patient and public
representative group with a specific interest in emergency care research. The Forum has reviewed this
proposal and provided feedback. Enid will continue to provide a link between the project and the Forum.
Enid previously spent eight years with Sheffield Community Health Council, was a lay member of the
Steering Committee for NHS Direct Yorkshire and Humber, was a member of Unscheduled Care Network
Board in Sheffield, spent three years with Sheffield Children’s Hospital Patient Forum, and has attended
Trust Board meetings at Sheffield Children’s Hospital for many years as an observer for the Community
Health Council and then the Patient Forum. She is now a member of Sheffield LINks (Local Involvement
Network), a lay member of the Out of Hours Accreditation Group, is on the Dental Services Joint Planning
Group for Sheffield, is a patient representative for the Group looking into Dentally Anxious Patients, and is
a patient representative on the new Critical Care/Emergency Medicine Priority Group.
Her role will include the following:
1. reviewing the protocol and specifically advising on ethical issues and arrangements for data protection
and confidentiality
2. reviewing the poster and information leaflet
3. patient/public representation on the Steering Committee
4. lay input into reporting and dissemination of findings
5. liaison between the project and the Sheffield Emergency Care Forum.
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Appendix 3 Standardised clinical assessment form
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Appendix 4 Schedule for the qualitative interviews
Pre-interview checks
l Introductions.
l Ensure that the participant is comfortable with the content of the information sheet and that any
questions are answered.
l Ensure that the participant is familiar with the PAINTED assessment form.
l Ensure that consent form is signed and dated.
l Ensure that interview details are completed.
Introduction
Briefly outline aims and objectives of the project and take participant details.
Participant information
Age:
Job title:
Length of employment at current site:
Length of employment within an emergency department setting:
Define clinical assessment form
General
Do you have experience of using clinical assessment forms in the emergency department?
l Other than the PAINTED form?
l Would you consider yourself to have significant experience of using such forms?
Would you consider yourself to have particularly strong views on clinical assessment forms?
l [If so] Are these positive or negative?
What is your general opinion of such forms?
l Could you explain why?
PAINTED Assessment Form
Thinking specifically about the PAINTED form . . .
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Do you have experience of using the PAINTED assessment form?
l How many forms have you completed?
l Have you completed an electronic or paper-based version of the form, or both?
What is your general opinion of the form?
l Could you explain why?
How would you assess the suitability of the form for its purpose [as a clinical
record] (acceptability)?
l What about in comparison to existing alternatives (both internal and external)?
l Could you explain why?
How easy do you think the form is to use (usability)?
l What about in comparison to other clinical assessment forms?
l Would you feel confident in using the form in a pandemic situation (that may be many years away)
with very little guidance?
l Could you explain why?
What do you like about the form?
l Could you explain why?
What do you dislike about the form?
l Could you explain why?
If you could alter the form in any way, how would you do so?
l Could you explain why?
Clinical assessment forms generally
Thinking about clinical assessment forms more generally . . .
How would you assess the suitability of the forms you have used in emergency department
practice [as clinical records]?
l Are there any specific examples you are thinking of?
l Could you explain why?
What is your reflection on how easy these have been to use?
l Are there any specific examples you are thinking of?
l Could you explain why?
In your opinion, do you think that you complete such forms thoroughly and accurately?
l Are there any factors that influence this?
l Do you believe these to be specific to your setting?
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If you were uncertain about how to complete a form, what would you do?
l Could you explain why?
How important a part of your clinical practice do you consider assessment forms to be?
l Could you explain why?
Electronic versus paper-based forms
Considering the use of electronic as well as paper-based forms . . .
Have you had experience of using both electronic and paper-based forms within the
emergency department?
l [If both] Would you consider yourself to have significant experience of using such forms?
How do you feel the two different types compare?
l Could you explain why?
If you could choose to use one or the other, which would it be?
l Could you explain why?
l Would your decision be the same if considering the specific example of the PAINTED form? Why?
Considering the increased use of information technology within healthcare, how do you see the
use of electronic forms developing within your emergency department?
l Do you consider there to be any barriers to this?
l Could you explain why?
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Appendix 5 Patient information leaflet (adult)
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